

CURRICULUM VITAE

Name: Guy VAN VLIET

Address, phone, fax, e-mail:

Business:

Research Center, Ste-Justine Hospital

3175 Ste-Catherine Road,

Montreal H3T 1C5, Quebec, Canada

Phone: (514) 345-4735

FAX: (514) 345-4988; e-mail: guy.van-vliet@recherche-ste-justine.qc.ca

Citizenships: Belgian and Canadian

EDUCATION, DEGREES AND CERTIFICATIONS

1976: M.D., summa cum laude, Université Libre de Bruxelles (ULB)

1977: Certificate from the Educational Commission for Foreign Medical Graduate (score: 86) and Visa Qualifying Examination, Philadelphia

1981: Certified Pediatrician (Belgium)

1986: Doctorate in Pediatrics ("Agrégation", Ph. D. equivalent), ULB

1989: Endocrinology Certification (Québec)

CLINICAL TRAINING

1976-1979: Pediatric residency, Saint-Pierre Hospital, ULB

1979-1980: Pediatric endocrinology residency, Saint-Pierre Hospital, ULB

RESEARCH TRAINING:

1978-1979: Part-time research, Interdisciplinary Research Institute, ULB

1979/06: Advanced Study Course: "Methods for Analyzing Human Growth & Development", Urbino, Italy

1980-1983: Pediatric endocrinology research fellowship, University of California, San Francisco

SCHOLARSHIPS

-from the Belgian government for the secondary school and medical studies.

-from the Fulbright Foundation, the North Atlantic Treaty Organization Scientific Research Program, Nordisk Insulin Laboratorium and the Foundation Princesse Marie-Christine for the fellowship in Pediatric Endocrinology (1980-1983)

APPOINTMENTS

1983-1987 Assistant (Assistant Professor), Pediatrics, ULB

1987-1989 Chef de clinique-adjoint (Assoc. Prof.), Pediatrics, ULB

1989-1995 Associate Professor, Pediatrics, Université de Montréal

1991-2013: Chief, Endocrinology Service, Sainte-Justine Hospital

1994-2010: Consultant, pediatric endocrinology, Rouyn Hospital (outreach)

1995-present: Professor of Pediatrics, Université de Montréal

2001-2002: Professeur Associé, Université Paris VII (sabbatical year)

CURRENT RESEARCH AREAS

Congenital hypothyroidism: pathophysiology, screening, management and outcome

Molecular genetics of congenital endocrinopathies

Efficiency trials and audits of procedures and treatments in pediatric endocrinology

HONORS AND AWARDS

1976: Fleurice Mercier Award (top medical school graduate, *ex æquo* with E. Cogan)

2004-2007: Faculty of 1000 Medicine, member (Thyroid section)
2006: Nominated, European Society for Paediatric Endocrinology Research Award
2012: Henning Andersen Award for best clinical abstract submitted to the European Society for Paediatric Endocrinology meeting (publication # 208)
2013: Award for best mentor from the foreign fellows at the Sainte-Justine Hospital

NATIONAL AND INTERNATIONAL AWARDS TO TRAINEES

(include co-supervisions, numbers refer to list of abstracts or publications)

1994: Canadian Pediatric Residents' Research Day, 1st prize, to P. Catellier (abstr 15)
1995: Assoc. Médecins Endocrinologues du Québec, 2^d prize, to D. Pacaud (abstr 17)
1996: Quebec Thyroid club, 1st prize to J.M. Dubuis (publication # 81)
1998: Quebec Thyroid club, 1st prize to L. Ward (publication # 94)
1998: Can. Soc. for Clinical investigation, 1st prize to L. Ward (publication # 102)
2001: ESPE H. Andersen Award (best of 800 abstracts), R.J.Perry (pub. # 116)
2003: Quebec Thyroid club, 1st prize to J. Simoneau-Roy (publication #130)
2004: ESPE *Hormone Research* prize to S. Tenoutasse (publication #121)
2006: John Bailey Prize for best presentation by a fellow (J. Deladoëy), Canadian Pediatric Endocrine Group Meeting, Edmonton, February 2006 (abstract # 72)
2006: Best oral presentation by a post-doc (J. Deladoëy), Graduate Students' Annual Congress, Sainte-Justine Hospital Research Center, June 2006 (abstract # 76)
2006: Best oral presentation by a resident (R.R. Scott), Canadian Society of Endocrinology and Metabolism, Toronto, October 2006 (publication # 155)
2007: 2nd prize *ex æquo*, presentation by graduate students/fellows (J. Deladoëy), Québec Thyroid Club, May 2007 (abstract 80)
2007: Best oral presentation by a resident, Canadian Society of Endocrinology and Metabolism, Vancouver, October 2007 (C.M. Girardin) (publication # 177)
2011: 1st prize, Presidential Poster session, The Endocrine Society (S. Wildi-Runge) (publication # 212)
2013: Presidential poster (awarded to the 50 highest rated abstracts out of > 1,500 submitted to the International Meeting of Pediatric Endocrinology, 2013 (C. Hasselmann) (publication #217)

MEMBERSHIP OF PROFESSIONAL SOCIETIES

- Groupe d'Étude pour une Réforme de la Médecine, Belgium, 1975-80.
- Belgian Pediatric Society (1978-2005).
- European Society for Pediatric Endocrinology (ESPE) since 1985.
- Endocrine Society since 1987.
- Honorary member, Japanese Society for Pediatric Endocrinology (1988).
- Lawson Wilkins Pediatric Endocrine Society (LWPES) since 1989.
- Canadian Society of Endocrinology and Metabolism 1989-2014.
- Founding member, Canadian Pediatric Endocrine Group (1996).
- Médecins Québécois pour le Régime Public/Canadian Doctors for Medicare, 2006-.

ACADEMIC/HOSPITAL COMMITTEES

- Organizing Committee, Symposium on Congenital Hypothyroidism (Brussels, 1988).
- Member, Canadian Growth Hormone Advisory Committee, 1989-1996.
- Drugs & Therapeutics Committee, LWPES (1991-1994).
- President, Provincial Committee for Growth Hormone Allocation (Ministry of Health, Province of Quebec), 1992-1996.
- Member, Personnel Awards Committee, Canadian Diabetes Association (1993-95).
- Member, Post-doctoral Fellowship Committee, Fonds de la Recherche en Santé du Québec (FRSQ) (1992 and 1993).
- President, 5th Canadian Humatrope Symposium, Mont Tremblant, Quebec (1993).

- Chair, Ph.D. Thesis Committee, H el ene Forget, University of Montreal, 1993.
- Performance and Safety Monitoring Reviewer, Clinical Trial: Androgen Effects on Cognition in Turner syndrome, NIH, 1995-2000.
- Royal College of Physicians and Surgeons of Canada: member of examination committee (Endocrinology, 95-96), corresponding member (Pediatrics, 98-00).
- Ph.D. Thesis Committee, Claudine Heinrichs, Universit e Libre de Bruxelles (2/96).
- Ph.D. Thesis Committee, Cathy Vaillancourt, University of Montreal, 1997.
- Research Ethics Committee, Sainte-Justine Hospital, 1996-1998.
- Scientific Committee, Research Center, Sainte-Justine Hospital, 1997-2001.
- Search Committee, Chief of Cardiology, Sainte-Justine Hospital, 1996-1997.
- Jury, Annual Graduate Student Presentations, Ste Justine Research Center, 06/98.
- Ph.D. Thesis Committee, George Zogopoulos, Exp. Medicine, Mc Gill Univ, 1998.
- Search Committee, Chairperson of Microbiology-Immunology, U of Montreal, 1999.
- Developmental Endocrinology Branch, NIH (site visit, 07/1999 & 10/2003).**
- Admission of pediatric residents, U of Montreal (member, 1999; **chair, 2003-2011**)
- Ph.D. Thesis Committee, Elena Torban, Exp. Medicine, Mc Gill University, 2000.
- Co-chair (w/Dr H.J. Guyda), 6th LWPES/ESPE Meeting, Montr al, 2001.**
- Strategic Planning Committee, ESPE, 2001-2002.
- Ph.D. Thesis Committee, Mireille Castanet, Universit e Paris-V, December 2002.
- Faculty promotion appeals Committee, Universit e de Montreal, 2003-07.
- Ph.D. Thesis Committee, Catheline Vilain, Universit e Libre de Bruxelles, March 2004.
- Program Organizing Committee, 7th Joint ESPE/LWPES Meeting, Lyon, 2005.
- President, Canadian Pediatric Endocrine Group, 2005-2007.**
- Faculty Promotions Committee, Dpt of Peds, U de Montr al, 2005-11 & 2014-18.
- Academic Affairs Committee, Ste-Justine Research Center, 2007-2013.
- Ph.D. Thesis Committee, Sylvia Sura-Trueba, Universit e Paris VII, June 2005.
- Ph.D. Thesis Committee, Andr e P. Van Trotsenburg, Amsterdam, July 2006.
- Ph.D Thesis Committee, Youssef Elhaji, McGill University, July 2006.
- Ph.D Thesis Committee, Gabor Szinnai, Universit e Paris VII, September 2008.
- Ph.D. Thesis Committee, Ren e Dallaire, Universit e Laval, February 2009.
- Global Pediatric Endocrinology and Diabetes and International Relationships Council of the Pediatric Endocrine Society, since 2011: expanding screening for congenital hypothyroidism worldwide.
- Search Committee, chief of Ob-Gyn, Centre Hospitalier de l'Universit e de Montr al, 2011 (Dean's representative).
- Search Committee, Chair, Dpt of Nutrition, U de M (Dean's representative), 2012 and 2013.
- Chair of M.Sc. thesis committee (Biomed. Sci., U de M), Sarah Thissier-L evy, 2012.
- Member of the Executive, Association des M edecins Cliniciens Enseignants de Montr al (AMCEM), June 2012- .
- Search Committee, chief of Ob-Gyn, H opital Maisonneuve-Rosemont, 2013 (Dean's representative).
- Academic Awards Committee, Dpt of Pediatrics, U de M, 2012-...
- The Endocrine Society's clinical practice task force on Medical Therapies for Hypothyroidism, 2012- .
- Member, course committee on Endocrinology and Reproduction, 2nd y med school, U of M, 1994-2001 and 2014- .
- Chair, Scientific Committee A, Ste-Justine Research Center, 2013-2017.
- Member, M.Sc. Scholarships committee, Fonds de Recherche Sant e-Qu ebec, 2014-2015.
- Scientific Committee, Newborn Screening Ontario, 2014-2015.

EDITORIAL ACTIVITIES

- Editor (with Dr Michel Polak) of the book "Thyroid Gland Development and Function", volume 10 in the Developmental Endocrinology Series (Series Editor: Martin O. Savage), Karger publishers, 2007.
- Contributor to 11 chapters in the "Dictionnaire de thérapeutique pédiatrique" (under the direction of Michel L. Weber), Presses de l'Université de Montréal, 1994.
- Contributor to 8 chapters in the "Dictionnaire de thérapeutique pédiatrique Weber", Éditions de la Chenelière, 2007.
- Editor (with Joseph E. Raine, Malcolm D.C. Donaldson and John W. Gregory) of the textbook *Practical Endocrinology and Diabetes in Children*, Third Edition, Wiley 2011.
- Associate Editor, *Hormone Research*, 2004-2011.
- Senior Editor, *Endocrinology-Diabetes-Metabolism Case Reports* (2013-....).
- Editorial Board: *Journal of Clinical Endocrinology and Metabolism* (1993-1996 and 2005-2008), *International Growth Monitor* (1996-2000), *Archives de Pédiatrie* (1996-2003), *Hormone Research in Pædiatrics* (1996-...).
- Reviewer of at least 30 papers a year for (in alphabetical order): *Ambulatory Pediatrics*, *American Journal of Human Genetics*, *American Journal of Obstetrics and Gynecology*, *American Journal of Pathology*, *American Journal of Physiology*, *Archives of Diseases in Childhood*, *Archives de Pédiatrie*, *Archives of Pediatrics and Adolescent Medicine*, *BMC Pediatrics*, *British Medical Journal*, *Clinical Endocrinology*, *Endocrine Journal*, *Endocrine Reviews*, *Endocrinology*, *European Journal of Endocrinology*, *European Journal of Human Genetics*, *European Journal of Pediatrics*, *Expert Review of Endocrinology and Metabolism*, *Hormone Research*, *Hormone and Metabolic Research*, *Human Molecular Genetics*, *International Growth Monitor*, *International Journal of Pediatrics*, *JAMA*, *Journal of Clinical Endocrinology and Metabolism*, *Journal of Clinical Investigation*, *Journal of Endocrinology*, *Journal of Genital Systems and Disorders*, *Journal of Inherited Metabolic Disease*, *Journal of Nutritional Biochemistry*, *Journal of Obstetrics and Gynecology*, *Journal of Pediatric Endocrinology and Metabolism*, *Journal of Pediatrics*, *Lancet*, *Nature Clinical Trials*, *Neuroendocrinology*, *Pediatric Pulmonology*, *Pediatric Research*, *Pediatrics*, *Pediatrics International*, *Sleep*, *Thyroid*.
- Reviewer of grants for: Canadian Diabetes Association, European Research Projects on Rare Diseases, Fonds de la Recherche en Santé du Québec, Fonds de la Recherche Scientifique Médicale and Actions de Recherche Concertées (Belgium), Hospital for Sick Children Foundation (Toronto), INSERM (France), Medical Research Council-Canadian Institutes for Health Research, Pediatric Oncology Group Ontario, Swiss National Science Foundation, LWPES.

RESEARCH GRANTS

- 1985-1988 Nutritional and metabolic influences on somatotrophic function in children. 1,000,000 BEF operating grant from Belgian Fund for Medical Research.
- 1988 Study of the interaction between growth hormone releasing hormone and dopaminergic tone in normal adult men. 223,000 BEF operating grant from Belgian Fund for Medical Research.
- 1989 Study of the mechanisms whereby glucagon stimulates the secretion of growth hormone in man. 224,000 BEF operating grant from Belgian Fund for Medical Research.
- 1989-1992 Hormonal control of growth in the genetically obese rat. 93,750\$ operating grant from the Research Center, Ste-Justine Hospital.
- 1992-1993 Hormonal control of growth in the genetically obese rat. 47,000\$ per year from the Canadian Diabetes Association.
- 1991-1995 Hormonal control of growth in the genetically obese rat. 72,000\$ per

- year from Biopedia Inc.
- 1995 Organization of a computerized registry of the hypopituitary children treated with growth hormone provided by the Ministry of Health, Province of Quebec, 20,000\$.
- 1997-1998 Hormonal control of growth in obesity. 59,819\$ from the Canadian Diabetes Association.
- 2001-2002 Multicenter RCT of episodic fluticasone vs placebo in viral-induced asthma in children (PI: F. Ducharme, local PI during maternity leave of N. Alos), MRC/PMAC, 283,578\$/y.
- 1999-2001 Bone density in women with Turner Syndrome (PI: S.P. Taback, Winnipeg), Eli Lilly/Winnipeg Children's Hospital Foundation.
- 1996-2007 Pathophysiology of pediatric thyroid diseases. 185,000\$, Ste-Justine Hospital Foundation (private donations, Mr John H. McCall MacBain).
- 2011-2013 Abnormal thyroid development: a model disorder for neurocognitive development and congenital malformations. European Society for Pediatric Endocrinology Research Unit, 112,000\$ (PI: Dr J. Deladoëy).
- 2009-present Pediatric thyroid diseases, 'Girafonds', CHU Ste-Justine Foundation (private donations). 600,000\$ (co-PI with Dr J. Deladoëy).
- 2015-2016: Genetic variants underlying isolated hyperthyrotropinemia: a pilot prevalence study from a provincial newborn screening cohort. 25,000 \$/y from the American Thyroid Association (PI: Jonathan Wasserman, Toronto).

TEACHING ACTIVITIES

Clinical teaching

- 1983-1989 Attending Physician, Pediatrics and Pediatric Endocrinology
Saint-Pierre Hospital and Children's Hospital, University of Brussels
- 1989-
Attending Physician, Pediatric Endocrinology, Ste-Justine Hospital

Formal teaching

- 1986-1988 General Pediatrics, 2^d yr, School of Nursing, Free Univ of Brussels
- 1989-1995 Sexual Differentiation and Puberty, 2^d y Med school, U of Montreal
- 1991-1997 Puberty, Graduate Program, University of Montreal
- 1992- Normal and Abnormal Growth, rotating interns, U of M, MMD 3503)
- 1993- Problem-based learning, Endocrinology and Reproduction (MMD #2233, 2nd year medical students (tutor, 1993-present)
- 2003- U of M graduate course to endocrinology residents and graduate students (U of M END # 8002): various assigned topics (thyroid, adrenal, sex differentiation)
- 2011, 2013-14: 2-hour interactive session on Interdisciplinarity, U of Montreal
- 2005-2010 European Society for Pediatric Endocrinology, Winter school faculty
- 2012-2014 European Society for Pediatric Endocrinology e-learning initiative: section on thyroid disorders in infancy, with Dr Line Chiniara
- 2014: Tutor, Ped. Endocrinol. Training Center in Africa, Nairobi (2 weeks)

Trainees (supervision or co-supervision)

<u>Name</u>	<u>Period of training</u>	<u>Present position</u>
J.C. Reiter, M.D.	1987-1988	Consultant, CHR Metz (FR)
Cl. Heinrichs, M.D.	1988-1989	Chief, Ped Endo, ULB
J.P. Chanoine, M.D.	1988-1989	Chief, Ped Endo, UBC
M. Simard, M.D.	1989-1990	Faculty, Univ of Utah
L. Nguyen-Yamamoto, B.Sc.	1990-1992	Post-doc, Mc Gill U
D. Pacaud, M.D.	1992-1994	Chief, Ped Endo, Calgary
J.M. Dubuis, M.D.	1992-1995	Private practice, Geneva
F. Richer, M.D.	summer 1993	Québec Publ. Health Inst.

P. (Voula) Tsagaroulis	summers 1994 & 95	Audiologist, Montreal
N. Alos, M.D.	1994-1995	Assoc Prof, U of Montreal
S.P. Taback, M.D.	1994-1998	Assoc Prof, U of Manitoba
N. Gagné, M.D.	1995-1997	Assoc. Prof, U Sherbrooke
L. M. Ward, M.D.	1996-1998	Research Chair, CHEO
S. Tenoutasse, M.D.	1997-1998	Staff, Ped Endo, Brussels
H. Devos, M.D.	1998-1999	Private practice, Gent
J. Simoneau-Roy, M.D.	2000-2002	Head, Ped Endo, Sherbr.
R. J. Perry, M.D.	2000-2002	Asst Prof, U. of Calgary
R. McEachern, M.D.	2000-2002	Asst Prof, Brown Univ.
D. Eugène, M.D.	2003-2004	Asst Prof, Laval Univ.
J. Gagné, M.D.	2002-2005	Asst Prof, Laval Univ.
M. Fillion, M.D.	2002-2007	Staff, Maisonneuve Hosp.
R. Scott, M.D.	2004-2007	Asst Prof, U of Montreal
Johnny Deladoëy, M.D., Ph.D.	2005-2007	Asst Prof, U of Montreal
Céline M. Girardin, M.D.	2006-2008	Staff Ped Endo, Geneva
Patricia Olivier, M.D.	2006-2008	Asst. Prof, U of Montreal
Diane Rottembourg, M.D.	2006-2009	Asst Prof, Sherbrooke U
Janet Saavedra, M.D.	2008-2009	Private practice, Ecuador
Sophie Stoppa-Vaucher, M.D.	2008-2010	Staff Ped Endo, Lausanne
Thomas Édouard, M.D., Ph.D.	2009-2011	Asst Prof, Toulouse
Steffi Wildi, M.D.	2009-2011	Staff Ped Endo, Zürich
Coralie Leblicq, M.D.	2009-2011	Ph.D student, Mc Gill
Caroline Hasselmann, M.D.	2011-2012	Staff, CHU, Tours
Francisca Grob, M.D.	summer 2012	Ped endocrinologist, Chile
Stéphanie Michaud, M.D.	2010-2014	Post-doctoral fellow
Lyne Chiniara, M.D.	2011-2013	Post-doctoral fellow
Despoina Manousaki, M.D.	2011-2014	Post-doctoral fellow
Martin Perslteyn, B.S.	2014-2015	Medical student
Chiraz Ghaddab, M.D., Ph.D.	2014-	Post-doctoral fellow
Karine Bourdet, M.D.	2015-	Post-doctoral fellow

PUBLICATIONS (*denote peer-reviewed original articles)

- 1.* **Van Vliet G**, Vainsel M, Wolter R, Heimann R. Growth failure, refractory anaemia and hypergammaglobulinaemia. *Acta Pediatr Belg* 31:41-44, 1978.
- 2.* Dorchy H, **Van Vliet G**, Toussaint D, Ketelbant-Balasse P, Loeb H. Mauriac Syndrome: three cases with retinal angiofluorographic study. *Diabète Metab* 3:195-200, 1979.
- 3.* **Van Vliet G**, Caufriez A, Robyn C, Wolter R. Plasma gonadotropin values in prepubertal cryptorchid boys: similar increase of FSH secretion in uni- and bilateral cases. *J Pediatr* 97:253-255, 1980.
4. Ernould Chr, Bourguignon JP, Lambrechts L, Craen M, Ducaju M, Malvaux P, **Van Vliet G**, Wolter R, Vanderschueren-Lodeweyckx M. Effects of spontaneous and testosterone induced puberty on height velocity, bone maturation and pubertal development in boys with hypopituitarism during hGH therapy. *Serono Symposium # 36 "Pathophysiology of Puberty"*. E. Cacciari and A. Prader, eds., Academic Press, London, NewYork, pp. 315-321, 1980.
5. Dorchy H, **Van Vliet G**. Cause of dwarfism in Mauriac syndrome. *J Pediatr* 98:857-858, 1981 (letter).
6. **Van Vliet G**, Vainsel M, Wolter R, Heimann R. Inhibition of growth hormone response in angiomatous lymphoid hyperplasia. *J Pediatr* 100:509, 1982 (letter).

- 7.* Roth RA, Maddux B, Wong KY, Styne DM, **Van Vliet G**, Humbel RE, Goldfine ID. Interactions of a monoclonal antibody to the insulin receptor with receptors for insulin-like growth factors. *Endocrinology* 112:1865-1867, 1983.
- 8.* Li CH, Yamashiro D, Gospodarowicz D, Kaplan SL, **Van Vliet G**. Total synthesis of insulin-like growth factor I (somatomedin C). *Proc Natl Acad Sci (USA)* 80:2216-2220, 1983.
- 9.* **Van Vliet G**, Styne DM, Kaplan SL, Grumbach MM. Growth hormone treatment for short stature. *N Engl J Med* 309:1016-1022, 1983.
- 10.* **Van Vliet G**, Styne DM, Kaplan SL, Grumbach MM. Hormone ontogeny in the ovine fetus XVI. Plasma immunoreactive somatomedin C/insulin-like growth factor-I in the fetal and neonatal lamb and in the pregnant ewe. *Endocrinology* 113:1716-1720, 1983.
- 11.* Cuttler L, **Van Vliet G**, Conte FA, Kaplan SL, Grumbach MM. Somatomedin C in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen therapy. *J Clin Endocrinol Metab* 60:1087-1092, 1985.
- 12.* Harris DA, **Van Vliet G**, Egli CA, Grumbach MM, Kaplan SL, Styne DM, Vainsel M. Somatomedin C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist. *J Clin Endocrinol Metab* 61:152-159, 1985.
- 13.* **Van Vliet G**, Bosson D, Robyn C, Craen M, Malvaux P, Vanderschueren-Lodeweyckx M, Wolter R. Effect of growth-hormone-releasing factor on plasma growth hormone, prolactin and somatomedin C in hypopituitary and short normal children. *Horm Res* 22:32-45, 1985.
14. **Van Vliet G**. Impaired growth hormone responses to growth hormone-releasing hormone in obesity. *N Engl J Med* 312:1326, 1985 (letter).
15. Rosenthal SM, Schriock EA, **Van Vliet G**, Silverman BL, Kaplan SL, Grumbach MM. Growth hormone-responsive short stature: current and prospective treatment. In: *Proceedings of the Symposium on Therapeutic Agents Produced by Genetic Engineering: Quo Vadis? The Example of Growth Hormone and its Releasing Factor*. A. Joyeaux, G. Leygue, M. Morre, R. Roncucci, P.H. Schmelck, eds., "Quovadis?" Symposium-Sanofi Group, Toulouse-Labège, France, pp. 325-334, 1985.
16. **Van Vliet G**, Wolter R. Biological manifestations of cryptorchidism with a practical scheme of testing according to age and a note on radiological investigations. *Comptes Rendus de la Société Belge de Pédiatrie* 17:19-23, 1985.
- 17.* **Van Vliet G**, Bosson D, Rummens E, Robyn C, Wolter R. Evidence against growth hormone releasing factor deficiency in children with idiopathic obesity. *Acta Endocrinol [Suppl]* 279:403-410, 1986.
18. **Van Vliet G**, Styne DM, Kaplan SL, Grumbach MM. Turner syndrome and hGH. Biochemical investigations. In: *Human Growth Hormone Research*. S. Raiti and R. Tolman, eds., Plenum, New York, pp. 115-122, 1986.
19. Styne DM, **Van Vliet G**, Rudolph AM, Kitterman J, Iwamoto H, Kaplan SL, Grumbach MM. Somatomedin C in the ovine foetus and neonate. In: *Human Growth Hormone*. S. Raiti and R. Tolman, eds. Plenum, New York, pp. 635-642, 1986.
20. **Van Vliet G**. Les troubles de la croissance chez l'enfant. Applications diagnostiques de la somatomédine C et de la somatocroinine. Thèse d'Agrégation de l'Enseignement Supérieur, Université Libre de Bruxelles, 1986.
- 21.* Raiti S, Moore WV, **Van Vliet G**, Kaplan SL. Growth stimulating effects of human growth hormone therapy in patients with Turner syndrome. *J Pediatr*

- 109:944-949, 1986.
- 22.* **Van Vliet G**, Glinoer D, Verelst J, Spehl M, Gompel C, Delange F. Cold thyroid nodules in childhood: is surgery always necessary? *Eur J Pediatr* 146:378-382, 1987.
- 23.* Raiti S, Kaplan SL, **Van Vliet G**, Moore WV. Short-term treatment of short stature and subnormal growth rate with human growth hormone. *J Pediatr* 110:357-361, 1987.
- 24.* Bourguignon JP, **Van Vliet G**, Vandeweghe M, Malvaux P, Vanderschueren-Lodeweyckx M, Craen M, Du Caju MVL, Ernould Chr. The treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin): the effect on adult height prognosis is related to its impairment before therapy. *Eur J Pediatr* 146:555-560, 1987.
- 25.* **Van Vliet G**, Bosson D, Craen M, Du Caju MVL, Malvaux P, Vanderschueren-Lodeweyckx M. Comparative study of the lipolytic potency of pituitary-derived and biosynthetic hGH in hypopituitary children. *J Clin Endocrinol Metab* 65:876-879, 1987.
- 26.* Chatelain P, Alamercury Y, Blanchard J, Boissel JP, Evain-Brion D, Morre M, Olivier M, Sizonenko P, **Van Vliet G**. Growth hormone response to a single IV injection of synthetic growth hormone-releasing factor GHRH-(1-44)-NH₂ in prepubertal children with growth failure. The GHRH European Multicenter Study. *J Clin Endocrinol Metab* 65:387-394, 1987.
27. **Van Vliet G**. Les pubertés précoces. *Rev Med Brux* 8:281-287, 1987.
28. **Van Vliet G**. Effet de l'irradiation cérébrale sur la croissance. A propos de deux observations. *Comptes Rendus de la Société Belge de Pédiatrie* 19:57-60, 1987.
- 29.* Bourguignon JM, Heinrichs C, **Van Vliet G**, Vandeweghe M, Vanderschueren-Lodeweyckx M, Malvaux P, Du Caju M, Craen M, Lambrechts L, Delire M, Ernould C. Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin. *Acta Endocrinol* 116:519-525, 1987.
- 30.* Caufriez A, Van Herweghem JL, Golstein J, Bosson D, **Van Vliet G**, Copinschi G. Low somatomedin-C (Sm-C) concentrations measured by direct radioimmunoassay in patients with chronic renal failure. *Reprod Nutr Develop* 27 (2B):567-568, 1987.
- 31.* Vandenbroeck J, Vanderschueren-Lodeweyckx M, Malvaux P, Craen M, **Van Vliet G**, Doods L, Eggermont E. Growth hormone deficiency: a hidden obstetrical trauma? *Eur J Obstet Gynecol Reprod Biol* 26:329-334, 1987.
32. **Van Vliet G**. Terapia della basa statura con ormone somatotropo. In: *Progressi nella diagnosi e terapia dei disturbi dell'accrescimento*. E.E. Müller, ed. pp. 289-301, 1987, Pythagora Press, Milan.
33. **Van Vliet G**. Hormonal changes during development in Turner syndrome. *Acta Paediatr Scand* 343 (suppl 1):31-37, 1988.
34. **Van Vliet G**. Somatomedines en andere groeifactoren. *Tijdschrift voor Kindergeneeskunde* 56 (suppl 1):11-14, 1988.
35. **Van Vliet G**. Growth hormone treatment of children with non-growth hormone deficient short stature. In: *Progress in Endocrinology 1988*. H.Imura, K.Shizume, S.Hoshida, eds., Excerpta Medica, International Congress Series 799:825-827, 1988.
36. **Van Vliet G**. Studies with growth hormone releasing factor in children. Diagnostic and therapeutic implications. *Acta Paediatr Jpn* 30 (suppl):68-71, 1988.
37. **Van Vliet G**, Barboni Th, Klees M, Cantraine F, Wolter R. Treatment strategy and long-term follow-up of congenital hypothyroidism. In: *Proceedings of the*

- NATO Advanced Research Workshop on Congenital Hypothyroidism. F. Delange, D. Glinoer, D.A. Fisher, eds., Plenum Press, pp. 245-252, 1989.
- 38.* Guerrier D, Tran D, Vanderwinden JM, Hideux S, Van Outryve L, Legeai L, Bouchard M, **Van Vliet G**, De Laet MH, Picard JY, Kahn A, Josso N. The persistent Müllerian duct syndrome: a molecular approach. *J Clin Endocrinol Metab* 68:46-52, 1989.
- 39.* De Hertogh R, Wolter R, **Van Vliet G**, Van Krieken L. Serum gonadotrophin levels in childhood. Critical comparison between immunoradiometric assays and radioimmunoassays. *Acta Endocrinol* 121:141-145, 1989.
- 40.* Massa G, Vanderschueren-Lodeweyckx M, **Van Vliet G**, Craen M, de Zegher F, Eggermont E. Hypothalamo-pituitary dysfunction in congenital toxoplasmosis. *Eur J Pediatr* 148:742-744, 1989.
41. Bourguignon JP, **Van Vliet G**. Factors influencing final height in hypopituitary patients. In: *Hormonal Regulation of Growth*. H. Frisch and M.O. Thorner, eds., Serono Symposia Publications from Raven Press, vol. 58, pp. 261-272, 1989.
42. Bourguignon JP, Vandeweghe M, Lambrechts L, Craen M, Du Caju MVL, Vanderschueren-Lodeweyckx M, **Van Vliet G**, Ernould C, Malvaux P. Hypopituitarism as a model of the relative effects of sex steroids and growth hormone on the pubertal growth spurt and final height. In: *Proceedings of the 3^d International Symposium on the Control of the Onset of Puberty*. H.A. Delemarre-Van de Waal *et al*, eds., Elsevier Science Publishers, pp. 329-342, 1990.
- 43.* Vanderschueren-Lodeweyckx M, Massa G, Maes M, Craen M, **Van Vliet G**, Heinrichs C, Malvaux P. Growth promoting effect of growth hormone and low-dose ethinylestradiol in girls with Turner syndrome. *J Clin Endocrinol Metab* 70:122-126, 1990.
- 44.* Christophe C, **Van Vliet G**, Doods G, Lemort M, Perlmutter N, Segebarth C, Balériaux D. Panhypopituitarism without diabetes insipidus: magnetic resonance imaging of pituitary stalk transection. *Eur J Pediatr* 149:235-236, 1990.
45. **Van Vliet G**. Use of growth hormone in the management of growth disorders. In: *Developmental Endocrinology*. P.C. Sizonenko and M.L. Aubert, eds., Serono Symposia Publications from Raven Press, vol. 67, pp. 196-202, 1990.
- 46.* Chanoine JP, Toppet V, Body JJ, **Van Vliet G**, Lagasse R, Bourdoux P, Spehl M, Delange F. Contribution of thyroid ultrasound and serum calcitonin to the diagnosis of congenital hypothyroidism. *J Endocrinol Invest* 13:97-102, 1990.
- 47.* Elmer C, **Van Vliet G**, Heinrichs C, Toppet M, Christophe C, Perlmutter-Cremer N, Vamos E. Nanisme à membres courts, dysmorphisme, dysplasie rénale, déficience en hormone de croissance avec hypoplasie pituitaire et retard psychomoteur: un nouveau syndrome? *J Genet Hum* 37:367-372, 1990.
- 48.* Vanderschueren-Lodeweyckx M, Massa G, Maes M, Craen M, **Van Vliet G**, Heinrichs C, Malvaux P. Groeihormoontherapie bij patienten met het syndroom van Turner. *Tijdschr voor Geneeskunde* 46:633-640, 1990.
- 49.* Christophe C, Balériaux D, Hanquinet S, Heinrichs C, Sariban E, Segebarth C, **Van Vliet G**, Perlmutter N. Apport de l'IRM dans 5 observations de diabète insipide central. *Pédiatrie* 45:505-510, 1990.
- 50.* Bergmann P, Valsamis J, Van Perborgh J, De Schepper J, **Van Vliet G**. Comparative study of the changes in insulin-like growth factor I (IGF-I), procollagen III N-terminal extension peptide (PC-III), bone GLA-protein (BGP) and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone (hGH). *J Clin Endocrinol Metab* 71:1461-1467,

- 1990.
51. Rebuffat E, Sottiaux M, Goyens P, Blum D, Vamos E, **Van Vliet G**, Haesaerts D, Steenhout P, De Meirleir L, Kahn A. Sudden infant death syndrome as first expression of a metabolic disorder. In: "Inborn errors of metabolism", Nestlé Nutrition Workshop Series, vol. 24, J. Schaub, F. Van Hoof, H.L. Vis, eds., pp. 71-80, 1991.
 - 52.* Massa G, Vanderschueren-Lodeweyckx M, Craen M, Vandeweghe M, **Van Vliet G**. Growth hormone treatment of Turner syndrome patients with growth hormone deficiency. *Eur J Pediatr* 150:460-463, 1991.
 53. Holland J, Brnjac L, Alexander D, Bailey J, Bala M, Best T, Bruce GA, Collu R, Couch R, Curtis J, Davis A, Dean H, Guyda H, Jenner M, Khoury K, MacMillan A, McArthur R, McCoy E, Rovet J, Salisbury S, Stephure D, Szots F, Sochett E, Tze J, Van der Meulen J, **Van Vliet G**. Turner's syndrome and final adult stature: a randomized controlled trial using human growth hormone and low dose ethinyl estradiol. In: Turner Syndrome: Growth Promoting Therapies. M.B. Ranke and R.G. Rosenfeld, eds., Excerpta Medica International Congress Series 924, Elsevier, Amsterdam, pp. 195-200, 1991.
 - 54.* Reiter JC, Craen M, **Van Vliet G**. Decreased growth hormone response to growth hormone releasing hormone in Turner's syndrome: relation to body weight and adiposity. *Acta Endocrinol* 125:38-42, 1991.
 - 55.* Chanoine JP, Vanderschueren-Lodeweyckx M, Maes M, Thiry-Counson G, Craen M, **Van Vliet G**. Growth hormone treatment in short normal children: absence of influence of time of injection and resistance to GH autofeedback. *J Clin Endocrinol Metab* 73:1269-1275, 1991.
 - 56.* Depasse C, Chanoine JP, Casimir G, **Van Vliet G**. Congenital hypothyroidism and cystic fibrosis. *Acta Paediatr Scand* 80:981-983, 1991.
 57. **Van Vliet G**. Clinical aspects of normal pubertal development. *Horm Res* 1991 36:93-96, 1991.
 - 58.* Lepage P, Van de Perre P, **Van Vliet G**, Nsengumuremyi F, Van Goethem C, Kestelyn P, Msellati P, Hitimana DG. Clinical and endocrinological manifestations in perinatally HIV-I infected children aged 5 years or more. *Am J Dis Child* 145:1248-1951, 1991.
 - 59.* Van Hauthem H, Toppet V, **Van Vliet G**. Congenital hypopituitarism: results of pituitary stimulation tests and of magnetic resonance imaging in a newborn girl. *Eur J Pediatr* 151:174-176, 1992.
 - 60.* de Zegher F, Vanderschueren-Lodeweyckx M, Heinrichs C, **Van Vliet G**, Malvaux P. Thyroid dysmorphogenesis: severe infantile hypothyroidism after normal neonatal thyroid stimulating hormone (TSH) screening. *Acta Paediatr* 81:274-276, 1992.
 - 61.* Van Maldergem L, Gillerot Y, Vamos E, Toppet M, Watillon P, **Van Vliet G**. Vasopressin and gonadotropin deficiency in a child with the ectrodactyly-ectodermal dysplasia-clefting syndrome. *Acta Paediatr Scand* 81:365-367, 1992.
 - 62.* Ferster A, Glinöer D, **Van Vliet G**, Otten J. Thyroid function during L-asparaginase therapy in children with acute lymphoblastic leukemia (ALL): difference between induction and late intensification. *Am J Pediatr Hematol Oncol* 14:192-196, 1992.
 - 63.* Lièvre M, Chatelain P, **Van Vliet G**, Olivier M, Blanchard J, Morre M, Boissel JP on behalf of the GHRH European Multicenter Study (GEMS) Group. Treatment with growth hormone-releasing hormone (GHRH) 1-44 in children with idiopathic growth hormone deficiency: a randomized double-blind dose-effect study. *Fundam Clin Pharmacol* 6:359-366, 1992.
 - 64.* Glorieux J, Dussault JH, **Van Vliet G**. Update on the intellectual development

- at the age of twelve years of children with congenital hypothyroidism diagnosed by neonatal screening. *J Pediatr* 121:581-584, 1992.
- 65.* **Van Vliet G**, Collu R. Treatment of Turner syndrome with growth hormone (letter). *J Pediatr* 122:671, 1993.
66. **Van Vliet G**. Modifications somatiques et métaboliques pendant la puberté. In: *Progrès en Andrologie #4: La puberté masculine et ses pathologies*. G. Arvis, M.G. Forest, P.C. Sizonenko, eds., Doin, Paris, pp. 63-69, 1993.
67. **Van Vliet G**, Delange F. Goiter and thyroiditis. In: *Pediatric Endocrinology*, 2nd edition. J. Bertrand, R. Rappaport, P.C. Sizonenko, eds., Williams & Wilkins, pp. 270-276, 1993.
68. Stephure DK, Holland FJ, Alexander D, Bailey J, Best T, Boulton BC, Bruce GA, Clarsen C, Collu R, Couch R, Curtis J, Daneman D, Dean H, Ehrlich R, Guyda H, Jenner M, Khoury K, Kitzen H, MacMillan A, Marshall HP, Morrison K, Perlman K, Rovet J, Salisbury S, Sochett E, Stewart L, Szots F, Tze J, Vander Meulen J, **Van Vliet G**. Human growth hormone and low dose ethinyl estradiol treatment in Turner syndrome: A prospective randomized controlled trial to final height. In: *Basic and Clinical Approach to Turner Syndrome*. I. Hibi and K. Takano, eds., Excerpta Medica International Congress Series 1014, Amsterdam, pp. 287-291, 1993.
- 69.* Nguyen-Yamamoto L, Deal CL, Finkelstein JA, **Van Vliet G**. Hormonal control of growth in the genetically obese Zucker rat. I. Linear growth, plasma insulin-like growth factor-I (IGF-I) and IGF-binding proteins. *Endocrinology* 134:1382-1388, 1994.
70. **Van Vliet G** and Deal C. Growth hormone and body fat: an overview of studies in hypopituitarism and in exogenous obesity. In: *Clinical issues in growth disorders: evaluation, diagnosis and therapy*. Serono Colloquia, vol 1 (A. Prader and R. Rappaport, editors), Freund Publishing House Ltd, pp 119-130, 1994.
- 71.* Dubuis JM, Deal CL, Drews RT, Goodyer CG, Lagacé G, Asa SL, **Van Vliet G**, Collu R. Mammosomatotroph adenoma causing gigantism in an 8-year old boy. A possible pathogenic mechanism. *Clin Endocrinol* 42:539-549, 1995.
- 72.* Heinrichs C, Deschepper J, Tsigos C, Drews R, Collu R, Dugardeyn C, Goyens P, Ghanem GE, Bosson D, Chrousos GP, **Van Vliet G**. Familial adrenocorticotropin unresponsiveness associated with alacrima and achalasia: biochemical and molecular studies in two siblings with clinical heterogeneity. *Eur J Pediatr* 154:191-196, 1995.
- 73.* Pacaud D, Huot C, Gattereau A, Brown RS, Glorieux J, Dussault JH, **Van Vliet G**. Outcome in three siblings with antibody-mediated transient congenital hypothyroidism. *J Pediatr* 127:275-277, 1995.
- 74.* Pacaud D, **Van Vliet G**, Delvin EE, Garel L, Chad Z, Delange F, Deal CL. A third world endocrine disease in a 6-year-old North American boy. *J Clin Endocrinol Metab* 80:2574-2576, 1995.
- 75.* Dubuis JM, Deal CL, **Van Vliet G**. The growth hormone (GH)-independent growth of the obese Zucker rat is not due to increased levels of GH receptor messenger RNA in the liver. *Mol Cell Endocrinol* 113:215-223, 1995.
- 76.* Chanoine JP, Rebuffat E, Kahn A, Bergmann P, **Van Vliet G**. Glucose, growth hormone, cortisol and insulin responses to glucagon injection in normal infants aged 0.5 to 12 months. *J Clin Endocrinol Metab* 80:3032-3035, 1995.
77. **Van Vliet G**. L'enfant de petite taille: doit-on s'inquiéter? *Le Clinicien*, Septembre 1995: 61-76.
78. Taback SP, **Van Vliet G** on behalf of The Canadian Growth Hormone Advisory Committee. Growth hormone, adult height, and psychosocial outcome in Turner syndrome: the need for controlled studies. In: *Turner syndrome in a*

- life-span perspective: research and clinical aspects. K. Albertsson-Wikland and M. Ranke, editors, Elsevier Science B.V., pp 183-190, 1995.
- 79.* Alos N, Huot C, Lambert R, **Van Vliet G**. Thyroid scintigraphy in pediatric Hashimoto's disease. *J Pediatr* 127:951-953, 1995.
80. Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society (including **Van Vliet G**). Guidelines for the use of growth hormone in children with short stature. *J Pediatr* 127: 857-867, 1995.
- 81.* Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, **Van Vliet G**. Outcome of severe congenital hypothyroidism: Closing the developmental gap with early high-dose levothyroxine treatment. *J Clin Endocrinol Metab* 81:222-227,1996 **(chosen as cover article)**.
- 82.* Taback SP, Dean HJ and members of the Canadian Growth Hormone Advisory Committee (including **Van Vliet G**). Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967-1992. *J Clin Endocrinol Metab* 81: 1693-1696, 1996.
- 83.* Dubuis JM, Deal, CL, Tsagaroulis P, Clark RG, **Van Vliet G**. Effects of 14-day infusions of growth hormone (GH) and/or insulin-like growth factor-I on the obesity of growing Zucker rats. *Endocrinology* 137:2799-2806, 1996.
- 84.* Tzanella M, Guyda HJ, **Van Vliet G**, Tannenbaum GS. Somatostatin analog pretreatment enhances growth hormone (GH) responsiveness to GH releasing hormone (GHRH): potential efficacy in the diagnosis of GH deficiency. *J Clin Endocrinol Metab* 81:2487-2494, 1996.
- 85.* Taback SP, Collu R, Deal CL, Guyda H, Salisbury S, Dean HJ, **Van Vliet G**. Does growth hormone supplementation affect adult height in Turner's syndrome? *Lancet* 348:25-27, 1996 **(accompanied by an Editorial)**.
86. **Van Vliet G**. Growth hormone treatment and adult height in Turner syndrome: do we need controlled studies? In: Turner syndrome across the life span (J. Rovet, editor), Klein Graphics, Markham, Ontario, pp 76-80, 1996.
- 87.* Collu R, Tang JQ, Castagné J, Lagacé G, Masson N, Huot C, Deal CL, Delvin E, Faccenda E, Eidne KA, **Van Vliet G**. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone gene. *J Clin Endocrinol Metab* 82: 1361-1365, 1997.
- 88.* Trifiro MA, Lumbroso R, Beitel LK, Bouchard J, Deal CL, **Van Vliet G**, Pinsky L. Impaired splicing due to insertion or substitution of thymine at position +3 of two splice-donor sites in the androgen receptor gene. *Eur J Hum Genet* 5: 50-58, 1997.
89. Taback SP, Deal C, **Van Vliet G**. Turner's syndrome (letter). *N Engl J Med* 336: 1527, 1997.
- 90.* Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, **Van Vliet G**, Costagliola S, Rodien P, Dumont JE, Vassart G. Diversity and prevalence of somatic mutations in the TSH receptor and Gs alpha genes as causes of toxic thyroid adenomas. *J Clin Endocrinol Metab* 82: 2695-2701, 1997.
91. **Van Vliet G**. Treatment and outcome of neonatal hypothyroidism. In: The Thyroid and Age (A. Pinchera, K. Mann and U. Hostalek, editors), Schattauer, Stuttgart/New York, pp 109-120, 1998 (see also publication # 99).
- 92.* Chanoine JP, Rebuffat E, Kahn A, **Van Vliet G**. Decreased growth hormone response to glucagon in infants after an apnea of infancy (AOI). *J Pediatr* 132: 452-454, 1998.
- 93.* Gagné N, Parma J, Deal C, Vassart G, **Van Vliet G**. Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? *J Clin Endocrinol Metab* 83: 1771-1775, 1998.

- 94.* Ward L, Chavez M, Huot C, Lecocq P, Collu R, Décarie JC, Martial JA, **Van Vliet G**. Severe congenital hypopituitarism with low prolactin levels and age-dependent pituitary hypoplasia: a clue to a PIT-1 mutation. *J Pediatr* 132:1036-1038, 1998.
95. Garel L, **Van Vliet G**. La différenciation sexuelle chez le fœtus. *Psychiatrie, Recherche et Évaluation en Santé mentale de l'Enfant*, Éditions de l'Hôpital Sainte-Justine, 8: 24-32, 1998.
- 96.* de Zegher F, Francois I, Boehmer AL, Saggese G, Muller J, Hiort O, Sultan C, Clayton P, Brauner R, Cacciari E, Ibanez L, **Van Vliet G**, Tiulpakov A, Saka N, Ritzen M, Sippell WG. Androgens and fetal growth. *Hormone Research* 50: 243-244, 1998.
97. **Van Vliet G**, Deal C. Growth hormone supplementation in Turner's syndrome. *J Pediatr* 113: 803, 1998 (letter).
98. Taback SP, **Van Vliet G**. Managing the short stature of Turner Syndrome: an evidence-based approach to the suggestion of growth hormone supplementation. In: *Current indications for growth hormone therapy* (PC Hindmarsh, editor), Karger, Basel, 1999, pp 102-117.
99. **Van Vliet G**. Neonatal hypothyroidism: treatment and outcome. *Thyroid* 9:79-84, 1999.
- 100.* Taback SP, Guyda HJ, **Van Vliet G**. Pharmacological manipulation of height: qualitative review of study populations and designs. *Clin Invest Med* 22: 53-59, 1999.
- 101.* Devos H, Rodd C, Gagne N, Laframboise R, **Van Vliet G**. A search for the possible molecular mechanisms of thyroid dysgenesis: sex ratios and associated malformations. *J Clin Endocrinol Metab* 84: 2502-2506, 1999.
- 102.* Ward L, Huot C, Lambert R, Deal C, Collu R, **Van Vliet G**. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine. *Clin Invest Medicine* 22: 132-139, 1999.
- 103.* Alos N, Moisan AM, Ward L, Desrochers M, Legault L, Leboeuf G, **Van Vliet G**, Simard J. A novel A10E homozygous mutation in the *HSD3B2* gene causing severe salt-wasting β -hydroxysteroid dehydrogenase deficiency in 46 XX and 46 XY French Canadians: evaluation of gonadal function after puberty. *J Clin Endocrinol Metab* 85: 1968-1974, 2000.
- 104.* Heinrichs C, Parma J, Scherberg NH, Delange F, **Van Vliet G**, Duprez L, Bourdoux P, Bergmann P, Vassart G, Refetoff S. Congenital central isolated hypothyroidism caused by abnormal TSH due to a homozygous mutation in the TSH-beta subunit gene. *Thyroid* 10: 387-391, 2000.
- 105.* Mircescu H, Parma J, Huot C, Deal C, Oligny LL, Vassart G, **Van Vliet G**. Hyperfunctioning malignant thyroid nodule in an eleven-year-old girl: pathological and molecular study. *J Pediatr* 137: 585-587, 2000.
106. Simard J, Ricketts ML, Moisan AM, Tardy V, Peter M, **Van Vliet G**, Morel Y. A new insight into the molecular basis of β -hydroxysteroid dehydrogenase deficiency. *Endocr Res* 26:761-70, 2000.
- 107.* MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, Ganguly A, Smith TJ, Stanley CA; Hyperinsulinism/hyperammonemia Contributing Investigators (including **Van Vliet G**). Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. *J Clin Endocrinol Metab*. 86: 1782-1787, 2000.
- 108.* Mircescu H, Wilkin F, Paquette J, Oligny LL, Decaluwe H, Gaboury L, Nolet S, **Van Vliet G**, Deal C. Molecular characterization of a pediatric pheochromocytoma with suspected bilateral disease. *J Pediatr* 138: 269-273, 2001.

109. **Van Vliet G**, Heinrichs C. Anomalies génétiques de l'axe thyroïdienne. In: La Thyroïde, 2^{ème} édition (sous la direction de J. Leclère, J. Orgiazzi, B. Rousset, J.L. Schlienger, J.L. Wémeau, éditeurs), pp 238-244, Elsevier, Paris, 2001.
110. **Van Vliet G**. Témoignage d'un pédiatre belge en poste à Montréal. L'Hôpital Belge 1: 9-12, 2001.
111. **Van Vliet G**. Treatment of congenital hypothyroidism. Lancet 358: 86-87, 2001 (invited commentary).
- 112.* Garel L, Dubois J, Grignon A, Filiatrault D, **Van Vliet G**. US of the pediatric female pelvis: a clinical perspective. Radiographics 21: 1393-1407, 2001.
- 113.* Zhang YH, Huang BL, Anyane-Yeboah K, Carvalho JA, Clemons RD, Cole T, De Figueiredo BC, Lubinsky M, Metzger DL, Quadrelli R, Repaske DR, Reyno S, Seaver LH, Vaglio A, **Van Vliet G**, McCabe LL, McCabe ER, Phelan JK. Nine novel mutations in NROB1 (DAX1) causing adrenal hypoplasia congenita. Hum Mutat 18: 547-551, 2001.
- 114.* Truong TL, Huot C, St-Louis P, **Van Vliet G**, Delvine EE. Contribution de l'insulinémie et de la leptinémie de base dans l'identification de l'intolérance glucidique chez les patients obèses. Ann. Biol. Clin. Qué 39(1):15, 2001.
- 115.* Massa GG, Heinrichs C, Vamos E, **Van Vliet G**. Hypergonadotropic hypogonadism in a boy with Fanconi's anemia, growth hormone deficiency and pituitary stalk interruption. J Pediatr 140: 277-278, 2002 (letter).
- 116.* Vincent MA, Rodd C, Dussault JH, **Van Vliet G**. Very low birth weight newborns do not need repeat screening for congenital hypothyroidism. J Pediatr 140: 311-314, 2002 (**accompanied by an Editorial**).
117. **Van Vliet G**. Molecular mechanisms of thyroid gland development: insights from clinical studies and from mutant mice. In: Developmental Endocrinology: from research to clinical practice (E.A. Eugster and O.H. Pescovitz, editors) (Contemporary Endocrinology Series, P.M. Conn, series editor), Humana Press, Totowa, New Jersey, 2002, pp 123-134.
- 118.* Perry RJ, Heinrichs C, Bourdoux P, Houry K, Szots F, Dussault JH, Vassart G, **Van Vliet G**. Discordance of monozygotic twins for thyroid dysgenesis: implications for screening and for molecular pathophysiology. J Clin Endocrinol Metab 87: 4072-4077, 2002 (**accompanied by an Editorial**).
- 119.* Muirhead S, Sellers EA, Guyda H, Canadian Pediatric Endocrine Group (including **Van Vliet G**). Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr. 2002 141: 247-252.
120. **Van Vliet G**. Childhood Endocrinology. In: Oxford Textbook of Endocrinology (S.M. Shalet and J.A.H. Wass, editors). Oxford University Press, 2002, pp 949-958.
121. **Van Vliet G**. Thyroid disorders in infancy. In: Pediatric Endocrinology, 4th Edition (Fima Lifshitz, editor). Marcel Dekker, New York, 2003, pp 347-358.
- 122*. Pulichino AM, Vallette-Kasic S, Couture C, Gauthier Y, Brue T, David M, Malpuech G, Deal C, **Van Vliet G**, Devroede M, Riepe FG, Partsch CJ, Sippel WG, Berberoglu M, Atasay B, Drouin J. Human and mouse *TPIT* gene mutations cause early onset ACTH deficiency. Genes and Development 17: 711-716, 2003.
- 123*. Tenoutasse S, **Van Vliet G**, Ledru E, Deal C. IGF-I transcript level in whole-liver tissue, in freshly isolated hepatocytes, and in cultured hepatocytes from lean and obese Zucker rats. Horm Res 59: 135-141, 2003.
- 124*. **Van Vliet G**, Larroque B, Bubuteishvili L, Supernant K, Léger J on behalf of the Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant. Sex-specific impact of congenital hypothyroidism from thyroid

- dysgenesis on skeletal maturation in term newborns. *J Clin Endocrinol Metab* 88: 2009-2013, 2003.
- 125*. **Van Vliet G**. Development of the thyroid gland: lessons from congenitally hypothyroid mice and men. *Clinical Genetics* 63: 445-455, 2003.
126. **Van Vliet G** and Czernichow P. Screening for neonatal endocrinopathies: rationale, methods and results. *Semin Neonatal* 9:75-85, 2004.
- 127*. **Van Vliet G**, Deal C, Crock P, Robitaille Y, Oligny LL. Sudden death in GH-treated children with Prader-Willi syndrome. *J Pediatr* 144:129-131, 2004.
128. Dubuis JM, **Van Vliet G**. Hypothyroidism, Congenital, Long-Term Follow-up, (L. Martini, ed.), *Encyclopedia of Endocrine Diseases*, Elsevier Inc, Amsterdam 2004, vol 2, pp 728-730.
129. **Van Vliet G**. Molecular mechanisms of normal and abnormal thyroid gland development. In: *Pediatric Endocrinology: Mechanisms, Manifestations and Management* (O.H. Pescovitz and E.A. Eugster, eds). Lippincott, Williams and Wilkins, 2004, pp 479-489.
- 130*. Djemli A, **Van Vliet G**, Belgoudi J, Lambert M, Delvin EE. Reference intervals for free thyroxine, total triiodothyronine, thyrotropin and thyroglobulin for Quebec newborns, children and teenagers. *Clin Biochem* 2004;37:328-330.
131. **Van Vliet G**. Thyroid radioiodine imaging is superior to ultrasonography in evaluating infants with congenital hypothyroidism (invited commentary). *Clinical Thyroidology* 2004;16:9.
- 132.* Simoneau-Roy J, Marti S, Deal C, Huot C, Robaey P, **Van Vliet G**. Cognition and behavior at school entry in children with congenital hypothyroidism treated early with high-dose levothyroxine. *J Pediatr* 144:748-753, 2004 (**accompanied by an Editorial**).
- 133.* McEachern R, Houle AM, Garel L, **Van Vliet G**. Lost and Found Testes: the importance of the hCG stimulation test and other testicular markers to confirm a surgical declaration of anorchia. *Horm Res* 62:124-128, 2004.
- 134.* Djemli A, Fillion M, Belgoudi J, Lambert R, Delvin EE, Schneider W, **Van Vliet G**. Twenty years later: a reevaluation of the contribution of plasma thyroglobulin to the etiological diagnosis of thyroid dysgenesis in infants with congenital hypothyroidism. *Clin Biochemistry*, 37:818-822, 2004.
135. **Van Vliet G**. Hypothyroidism in infants and children. In *The Thyroid*, 9th Edition (L.E. Braverman and R.D. Utiger, eds), chapter 75, Lippincott, Williams and Wilkins, 2005, pp 1029-1047.
- 136.* Vallette-Kasic S, Pulichino AM, Gueydan M, Barlier A, David M, Nicilono M, Malpuech G, Déchelotte P, Deal C, **Van Vliet G**, De Vroede M, Riepe FG, Partsch CJ, Sippel WG, Berberoglu M, Atasay B, de Zegher F, Beckers D, Kylo J, Donohoue P, Fassnacht M, Hahner S, Noordam K, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Léger J, Brauner R, Heinrich JJ, Cummings E, Riddell C, Enjalbert A, Brue T, Drouin J. Congenital isolated ACTH deficiency, an underestimated cause of neonatal death, explained by TPIT mutations. *JCEM*, 90: 1323-1321, 2005.
- 137.* Sobrier ML, Netchine I, Heinrichs C, Thibaud N, Vie-Luton MP, **Van Vliet G**, Amselem S. Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. *Hum Mutat* 25:503, 2005.
- 138.* Huang N, Pandey AV, Agrawal V, Reardon W, Bonaventure J, Lapunzina PD, Mowatt D, Okamjima K, Jabs EW, **Van Vliet G**, Sack J, Flück CE, Miller WL. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. *Am J Hum Genet* 76: 729-749, 2005.

- 139.* Eugène D, Djemli A, **Van Vliet G**. Sexual dimorphism of thyroid function in newborns with congenital hypothyroidism. *J Clin Endocrinol Metab* 90:2696-2700, 2005.
- 140.* Perry RJ, Kecha O, Paquette J, Huot C, **Van Vliet G**, Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. *J Clin Endocrinol Metab* 90: 3243-3250, 2005.
- 141.* The Canadian Growth Hormone Advisory Committee (including **Van Vliet G**., member of the steering and writing committees). Impact of Growth Hormone supplementation on adult height in Turner syndrome: Results of the Canadian randomized controlled trial. *J Clin Endocrinol Metab* 90: 3360-3366, 2005 **(accompanied by an Editorial)**.
142. **Van Vliet G**. How often should we screen children with Down's syndrome for hypothyroidism? (invited commentary). *Archives of Diseases in Childhood*, 90: 557-558, 2005.
- 143.* Grasberger H, Mimouni-Bloch A, Vantyghem C, **Van Vliet G**, Abramowicz M, Metzger DL, Abdulatif H, Rydlewski C, Machia PE, Scherberg NH, Van Sande J, Weiss RE, Vassart G, Refetoff S. Autosomal dominant resistance to thyrotropin as a novel entity in five multigenerational kindreds: clinical characterization and exclusion of candidate loci. *J Clin Endocrinol Metab* 90:4025-4034, 2005.
144. **Van Vliet G**. Longitudinal study of thyroid function in Down's syndrome in the first two decades. *Current Best Evidence, J. Pediatr* 147: 707-708, 2005 (invited commentary).
145. **Van Vliet G**. Neonatal endocrinopathies: should we change the screening methods? (invited editorial). *Italian Journal of Pediatrics* 31: 209-12, 2005.
- 146.* Stein R, Wherrett D, Daneman D, in collaboration with the Canadian Pediatric Endocrine Group (including **Van Vliet G**, member). Management of 21-hydroxylase deficiency congenital adrenal hyperplasia: a survey of Canadian pediatric endocrinologists. *Pediatr Child Health* 10: 323-326, 2005.
147. Carranza D, **Van Vliet G**, Polak M. Hyperthyroïdie et hypothyroïdie du nouveau-né et de l'enfant. *Encyclopédie Médico-Chirurgicale*, Elsevier 2006, pp 1-11.
148. Carranza D, **Van Vliet G**, Polak M. Hypothyroïdie congénitale. *Ann Endocrinol (Paris)* 67: 295-302, 2006.
149. Djemli A, **Van Vliet G**, Delvin EE. Congenital hypothyroidism: From Paracelsus to molecular diagnosis. *Clin Biochem.* 39:511-518, 2006.
- 150*. Hamelin C, Anglin G, Quigley C, Deal C, on behalf of the Canadian Growth Hormone Advisory Committee (including **Van Vliet G**., member of the steering committee). Genomic imprinting in Turner Syndrome: Effects on response to growth hormone and on risk of sensorineural hearing loss. *J Clin Endocrinol Metab* 91:3002-3010, 2006.
- 151.* Marti S, Alvarez M, Simoneau-Roy J, Leroux S, **Van Vliet G**, Robaey P. Effects of early high-dose levothyroxine treatment on auditory brain event-related-potentials at school entry in children with congenital hypothyroidism. *Hormone Research*, 66:240-248, 2006.
- 152.* Cerrato F, Shagoury J, Kralickova M, Dwyer A, Falardeau J, Ozata M, **Van Vliet G**, Bouloux P, Hall JE, Hayes FJ, Pitteloud N, Martin KA, Welt C, Seminara SB. Coding sequence analysis of GNRHR and GPR54 in patients with congenital and adult-onset forms of hypogonadotropic hypogonadism. *Eur J Endocrinol.*155 Suppl 1:S3-S10, 2006.
- 153.* Fillion M, Deal CL, **Van Vliet G**. Normal minipuberty of infancy in boys with Prader-Willi syndrome. *J Pediatr* 149: 874-876, 2006.

- 154.* Grosse SD, **Van Vliet G**. How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia? *Horm Res*. 67:284-291, 2007.
- 155.* Grosse SD, **Van Vliet G**. Outcomes in CAH: Need for evidence-based estimates (letter). *Horm Res*;68: 203, 2007.
156. **Van Vliet G**. Congenital Hypothyroidism: Look at the Whole Patient! (Editorial comment). *Horm Res* 68: 276-277, 2007.
- 157.* Scott RR, Gomes LG, Huang N, **Van Vliet G**, Miller WL. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. *J Clin Endocrinol Metab*. 92: 2318-2322, 2007.
- 158.* Deladoëy J, Belanger N, **Van Vliet G**. Random variability in congenital hypothyroidism from thyroid dysgenesis over 16 years in Quebec. *J Clin Endocrinol Metab*. 92:3158-3161, 2007.
159. **Van Vliet** , Polak M. Thyroid disorders in infancy. In: *Pediatric Endocrinology*, 5th Edition (Fima Lifshitz, editor). Informa Health Care, New York, 2007, vol 2, pp 390-404.
160. Deladoëy J, Vassart G, **Van Vliet G**. Possible non-mendelian mechanisms of thyroid dysgenesis. *Endocr Dev*. 2007;10: 29-42.
161. **Van Vliet G**. Intellectual outcome of children with severe congenital hypothyroidism: treating at 20 days of life is not early enough. *J Clin Endocrinol Metab* 2007 (electronic letter discussing article by Kempers et al, *J Clin Endocrinol Metab*. 2007 Mar;92(3):919-24).
- 162.* Carré A, Castanet M, Sura-Trueba S, Szinnai G, **Van Vliet G**, Trochet D, Amiel J, Léger J, Czernichow P, Scotet V, Polak M. Polymorphic length of FOXE1 alanine stretch: evidence for genetic susceptibility to thyroid dysgenesis. *Hum Genet* 122:467-476, 2007.
163. Ducharme JR, **Van Vliet G**. L'endocrinologie pédiatrique à Sainte-Justine de 1959 à 2006. *La petite histoire de Sainte-Justine 1907-2007* (sous la direction de C.C. Roy), Éditions du CHU Sainte-Justine, 2007, pp 165-167.
- 164.* Deladoëy J, Pfarr N, Vuissoz JM, Parma J, Vassart G, Biesterfeld S, Pohlenz J, **Van Vliet G**. Pseudodominant inheritance of goitrous congenital hypothyroidism caused by TPO mutations: molecular and in silico studies. *J Clin Endocrinol Metab* 93:627-633, 2008.
- 165.* Ahmed S, Delvin E, Hamilton J on behalf of the Canadian Pediatric Endocrine Group (including **Van Vliet G**, member). Variation in Growth Hormone Immunoassay in Clinical Practice in Canada. *Horm Res* 69: 290-294, 2008.
- 166.* Arbuckle TE, Hauser R, Swan SH, Mao CS, Longnecker MP, Main KM, Whyatt R, Mendola P, Legrand M, Rovet J, Till C, Wade M, Jarrell J, Mathews S, **Van Vliet G**, Bornehag CG, Mieusset R. Meeting Report: Measuring Endocrine-Sensitive Endpoints within the First Years of Life. *Environ Health Perspect*: 116: 948-951, 2008.
- 167.* Cole LW, Sidis Y, Zhang C, Quinton R, Plummer L, Pignatelli D, Hughes VA, Dwyer AA, Raivio T, Hayes FJ, Seminara SB, Huot C, Alos N, Speiser P, Takeshita A, **Van Vliet G**, Pearce S, Crowley WF Jr, Zhou QY, Pitteloud N. Mutations in Prokineticin 2 (PROK2) and PROK2 Receptor (PROKR2) in Human Gonadotrophin-Releasing Hormone Deficiency: Molecular Genetics and Clinical Spectrum. *J Clin Endocrinol Metab* 93: 3551-3559, 2008.
- 168.* Khatchadourian K, Huot C, Alos N, **Van Vliet G**, Deal C. Impact of Patient Characteristics and Clinical Factors on the Decision to Initiate Growth Hormone Treatment in Turner Syndrome. *Horm Res*. 70:300-308, 2008.
169. **Van Vliet G**, Polak M, Ritzén EM. Treating fetal thyroid and adrenal disorders through the mother. *Nat Clin Pract Endocrinol Metab*. 4, 675-682, 2008.

- 170.* Fillion M, Deal C, **Van Vliet G**. Retrospective Study of the Potential Benefits and Adverse Events during Growth Hormone Treatment in Children with Prader-Willi Syndrome. *J Pediatr* 154:230-233, 2009.
- 171.* Maquet E, Costagliola S, Parma J, Christophe-Hobertus C, Oligny LL, Fournet JC, Robitaille Y, Vuissoz JM, Payot A, Laberge S, Vassart G, **Van Vliet G**, Deladoëy J. Lethal respiratory failure and mild primary hypothyroidism in a term girl with a de novo heterozygous mutation in the TITF1/NKX2.1 gene. *J Clin Endocrinol Metab* 94: 197-203, 2009.
172. Polak M, **Van Vliet G**. Disorders of the Thyroid Gland. Chapter 26 in *Pediatric Endocrinology and Innborn Errors of Metabolism* (K. Sarafoglou, G. F. Hoffmann and K.S. Roth, editors). Mc Graw-Hill, 2009 (pp 355-382).
- 173.* Girardin CM, Lemyre E, Alos N, Deal C, Huot C, **Van Vliet G**. Comparison of adolescents with Klinefelter syndrome according to the circumstances of diagnosis: amniocentesis versus clinical signs. *Horm Res* 72:98-105, 2009.
174. **Van Vliet G**. Genetics and epigenetics of congenital hypothyroidism. Chapter 9 in *Clinical Management of Thyroid Disease* (F.E. Wondisford and S. Radovick, editors), Elsevier, 2009 (pp 113-121).
- 175.* Vilain C, Mortier G, **Van Vliet G**, Dubourg C, Heinrichs C, de Silva D, Verloes A, Baumann C. Hartsfield holoprosencephaly-ectrodactyly syndrome in five male patients: Further delineation and review. *Am J Med Genet.* 149A:1476-1481, 2009.
- 176.* **Van Vliet G**, Liu S, Kramer MS, for the Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. Decreasing sex difference in birth weight. *Epidemiology* 20:622, 2009.
- 177.* Girardin CM, Deal C, Lemyre E, Paquette J, Lumbroso R, Beitel LK, Trifiro MA, **Van Vliet G**. Molecular studies of a patient with complete androgen insensitivity and a 47,XXY karyotype. *J Pediatr* 155:439-443, 2009.
- 178.* Raivio T, Sidis Y, Plummer L, Chen H, Ma J, Mukherjee A, Jacobson-Dickman E, Quinton R, **Van Vliet G**, Lavoie H, Hughes VA, Dwyer A, Hayes FJ, Xu S, Sparks S, Kaiser UB, Mohammadi M, Pitteloud N. Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 94:4380-4390, 2009.
- 179.* **Van Vliet G**, Vassart G. Monozygotic twins are generally discordant for congenital hypothyroidism from thyroid dysgenesis. *Horm Res* 72:320, 2009.
- 180.* Rottembourg D, O'Gorman CS, Urbach S, Garneau PY, Langer JC, **Van Vliet G**, Hamilton J, Huot C. Outcome after bariatric surgery in two adolescents with hypothalamic obesity following treatment of craniopharyngioma. *J Pediatr Endocrinol Metab* 22:867-872, 2009.
181. Pohlenz J, **Van Vliet G**. Developmental abnormalities of the thyroid. Chapter 9 in *Genetic Diagnosis of Endocrine Disorders* (Roy E. Weiss and Samuel Refetoff, editors), 2010 (pp 97-104).
182. Djemli A, **Van Vliet G**, Delvin EE. Biochemical Evaluation of Thyroid Gland Disorders in Children. *Biochemical and Molecular Basis of Pediatric Disease*, 4th edition (D.J. Dietzen, M.J. Bennett and E.C.C. Wong, editors), AAC Press 2010 (pp 155-170).
- 183.* Hoste C, Rigutto S, **Van Vliet G**, Miot F, De Deken X. Compound heterozygosity for a novel hemizygous missense mutation and a partial deletion affecting the catalytic core of the H₂O₂-generating enzyme DUOX2 associated with transient congenital hypothyroidism. *Human Mutation* 31: E1304-1319, 2010.

184. Polak M, **Van Vliet G**. Therapeutic Approach of Fetal Thyroid Disorders. *Horm Res Paediatr* 74:1-5, 2010.
- 185.* Stoppa-Vaucher S, Francoeur D, Grignon A, Alos N, Pohlenz J, Hermanns P, **Van Vliet G**, Deladoëy J. Non-immune goiter and hypothyroidism in a 19-week fetus: A plea for conservative management. *J Pediatr* 156: 1026-1029, 2010.
186. Leblicq C, **Van Vliet G**. Does long-term growth hormone therapy change the natural history of body composition and motor function in children with Prader-Willi syndrome? *J Clin Endocrinol Metab* online, June 3, 2010 (letter discussing article by Carrel et al, *J Clin Endocrinol Metab*. 2010 Mar;95(3):1131-6).
- 187.* Stoppa-Vaucher S, Djemli A, **Van Vliet G**. Undetectable AMH at 3 days of age: a clue to bilateral anorchia. *Clin Biochem*. 43:1373-4, 2010.
- 188.* Stoppa-Vaucher S, **Van Vliet G**, Deladoëy J. Variation by Ethnicity in the Prevalence of Congenital Hypothyroidism due to Thyroid Dysgenesis. *Thyroid* 21:13-18, 2011.
- 189.* Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, **Van Vliet G**, Grüters A, Eunice M, Hafez M, Hochberg Z, Lala R, Al Mawlawi H, del Valle Nuñez CJX, Servant N, Lumbroso S, Paris F, Sultan C. Phenotypical, biological and molecular heterogeneity of 5 α -reductase deficiency: an extensive international experience of 55 patients. *J Clin Endocrinol Metab* 96:296-307, 2011.
- 190.* Leblicq C, Rottembourg D, Deladoëy J, **Van Vliet G**, Deal C. Are guidelines for glucocorticoid coverage in adrenal insufficiency currently followed? *J Pediatr* 158:492-498, 2011.
- 191.* Saavedra J, Deladoëy J, Saint-Vil D, Boivin Y, Alos N, Deal C, **Van Vliet G**, Huot C. Is ultrasonography useful in predicting thyroid cancer in children with thyroid nodules and apparently benign cytopathologic features? *Horm Res Paediatr* 75: 269-275, 2011.
- 192.* Grosse SD, **Van Vliet G**. Prevention of intellectual disability through screening for congenital hypothyroidism: how much and at what level? *Arch Dis Child* 96:374-379, 2011.
193. Rottembourg D, **Van Vliet G**. Lingual mass in a neonate: do not forget the thyroid. *Arch Dis Child* (e-letter published April 18, 2011, discussing article by Joolay Y, Stewart C in *Arch Dis Child Fetal Neonatal Ed*. 2011 Jul;96(4):F258. Epub 2011 Mar 22).
- 194.* Taback SP, **Van Vliet G**. Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant growth hormone. *BMC Pediatrics* May 29, 11:49, 2011.
- 195.* Girardin CM, **Van Vliet G**. Counseling of a couple faced with a prenatal diagnosis of Klinefelter syndrome. *Acta Paediatr* 100: 917-922, 2011.
196. Grosse SD, **Van Vliet G**. The remaining health burden of congenital hypothyroidism in the era of neonatal screening (invited editorial). *J Clin Endocrinol Metab* 96: 1671-1673, 2011.
- 197.* Tornberg J, Sykiotis GP, Keefe K, Plummer L, Hoang X, Hall JE, Quinton R, Seminara SB, Hughes V, **Van Vliet G**, Van Uum S, Crowley WF, Habuchi H, Kimata K, Pitteloud N, Bülow HE. Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism. *Proc Natl Acad Sci U S A* 108:11524-11529, 2011.

198. Stoppa-Vaucher S, **Van Vliet G**, Deladoëy J. Discovery of a Fetal Goiter on Prenatal Ultrasound in Women Treated for Graves' Disease: First, Do No Harm. *Thyroid* 21: 931, 2011.
- 199.* Deladoëy J, Ruel J, Giguère Y, **Van Vliet G**. Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Québec. *J Clin Endocrinol Metab* 96: 2422-2499, 2011.
200. **Van Vliet G**. Childhood Endocrinology. In: *Oxford Textbook of Endocrinology* (J.A.H. Wass and P.M. Stewart, editors). Oxford University Press, 2nd edition, 2011, pp 1006-1013.
- 201.* McEachern R, Drouin J, Metherell L, Huot C, **Van Vliet G**, Deal C. Severe cortisol deficiency associated with reversible growth hormone deficiency in two infants: what is the link? *J Clin Endocrinol Metab* 96: 2670-2674, 2011.
- 202.* Edouard T, Deal C, **Van Vliet G**, Gaulin N, Moreau A, Rauch F, Alos N. Muscle-bone characteristics in children with Prader-Willi syndrome. *J Clin Endocrinol Metab* 97: E275-E281, 2012.
- 203.* Wildi-Runge S, Stoppa-Vaucher S, Lambert R, Turpin S, **Van Vliet G**, Deladoëy J. A high prevalence of dual thyroid ectopy in congenital hypothyroidism: evidence for insufficient signaling gradients during embryonic thyroid migration or for the polyclonal nature of the thyroid gland? *J Clin Endocrinol Metab* 97: E978-81, 2012.
- 204.* Olivier P, Simoneau-Roy J, Francoeur D, Sartelet H, Parma J, Vassart G, **Van Vliet G**. Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. *J Pediatr* 161:1147-1152, 2012.
205. **Van Vliet G** and Deladoëy J. Hypothyroidism in infants and children. In: *The Thyroid*, 10th Edition (LE Braverman and DS Cooper, eds), chapter 54, Lippincott, Williams and Wilkins, 2013, pp 787-802.
206. Zacharin M, Chanoine JP, Cassorla F, Brink S, Hanas R, Fideleff HL, Oduwole A, Shah N, Hochberg Z; on behalf of all 70 Global Pediatric Endocrinology and Diabetes Active Members (including **Van Vliet G**). Promoting Excellence in the Care of Pediatric Endocrine Diseases in the Developing World. *Pediatrics* 131: e573-578, 2013.
- 207.* Leblcq C, Duval M, Carmant L, **Van Vliet G**, Alos N. Chorea in Graves' Disease is due to Rising Serum Thyroxine Levels, not to Autoimmunity. *Pediatrics* 131: e616-e619, 2013.
- 208.* Samuels ME, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, Chouinard L, Schwartzentruber J, René P, Sawyer N, Bouvier M, Djemli A, Delvin E, Huot C, Deal CL, **Van Vliet G**, Majewski J and Deladoëy J. Bioinactive ACTH causing glucocorticoid deficiency. *J Clin Endocrinol Metab* 98: 736-742, 2013.
- 209.* Hasselmann C, Deladoëy J, Vuissoz JM, Patry L, Alirezaie N, Schwartzentruber J, FORGE Canada Consortium, Deal CL, **Van Vliet G**, Majewski J, Samuels ME. Expanding the phenotypic spectrum of nicotinamide nucleotide transhydrogenase (*NNT*) mutations and using whole exome sequencing to discover potential disease modifiers. *Journal of Genomes and Exomes* 1: 19-30, 2013.
210. Deladoëy J, **Van Vliet G**. Treating congenital hypothyroidism – which levothyroxine? *Nat. Rev. Endocrinol.* 9, 257–258, 2013.
- 211.* Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Wilson Chung BF, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley Jr WF, Seminara SB, Quinton R, Hughes VA, Kumanov Ph, Young J, Yialamas MA, Hall JE, **Van Vliet G**, Chanoine JP, Rubenstein J, Mohammadi M, Tsai P-S, Sidis Y, Lage K, Pitteloud N. Genetic screening of the FGF8 synexpression

- group identifies rare sequence variants in FGF17, IL17RD, DUSP6, SPRY4 and FLRT3 in patients with Congenital Hypogonadotropic Hypogonadism. *Am J Hum Genet* 92, 725–743.
- 212.* Wildi-Runge S, Deladoëy J, Bélanger C, Deal C, **Van Vliet G**, Alos N, Huot C. A search for variables predicting cortisol response to low dose corticotropin stimulation following suprphysiological doses of glucocorticoids. *J Pediatr* 163: 484-488, 2013.
- 213.* Sharkia M, Michaud S, Berthier MT, Giguère Y, Metzger D, Stewart L, Deladoëy J, Deal CL, **Van Vliet G**, Chanoine JP. Thyroid function from birth to adolescence in Prader-Willi Syndrome. *J Pediatr* 163: 800-805, 2013.
- 214.* Simonis N, Migeotte I, Lambert N, Perazzolo C, de Silva DC, Dimitrov B, Heinrichs C, Janssens S, Kerr B, Mortier G, **Van Vliet G**, Lepage P, Casimir G, Abramowicz M, Smits G, Vilain C. FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly. *J Med Genet* 50: 585-592.
- 215.* Chiniara L, Perry RJ, **Van Vliet G**, Huot C, Deal C. Quality of referral of short children to the pediatric endocrinology clinic and impact of a fax communication system. *Paediatrics and Child Health* 18: 533-7, 2013.
- 216.* Samuels ME, Hasselmann C, Deal CL, Deladoëy, **Van Vliet G**. Whole-exome sequencing: opportunities in pediatric endocrinology. *Personalized Medicine* 11: 63-78, 2014.
- 217.* Grob F, Deladoëy J, Legault L, Spigelblatt L, Fournier A, Vassart G, **Van Vliet G**. Autonomous Adenomas Caused by Somatic Mutations of the Thyroid-Stimulating Hormone Receptor in Children. *Horm Res Paediatr* 29:73-79, 2014.
218. **Van Vliet G**, Deladoëy J. Thyroid disorders in the newborn and infant. In: *Pediatric Endocrinology*, 4th edition (M.A. Sperling, editor), pp 186-208, 2014.
219. Léger J, Olivieri A, Donaldson M, Torresani T, Krude H, **Van Vliet G**, Polak M, Butler G, on behalf of ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE and the Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology Consensus Guidelines on Screening, Diagnosis, and Management of Congenital Hypothyroidism. *J Clin Endocrinol Metab* 99: 363-384, 2014.
220. Deladoëy J, **Van Vliet G**. The changing epidemiology of congenital hypothyroidism: fact or artifact? *Expert Review in Endocrinology and Metabolism* 9: 1-9, 2014.
- 221.* Abu-Khudir R, Magne F, Chanoine JP, Deal C, **Van Vliet G**, Deladoëy J. Role for tissue-dependent methylation differences in the expression of *FOXE1* in non-tumoral thyroid glands. *J Clin Endocrinol Metab* 99: E1120-1129, 2014
222. **Van Vliet G**, Deladoëy J. Congenital Hypothyroidism: diagnosis, treatment, outcome. *Endocr Dev.* 26:50-9, 2014.
223. Szinnai G, Léger J, Bauer AJ, Pearce EN, Ramos HE, Canalli MH, Onigata K, Elisei R, Radetti G, Polak M, **Van Vliet G**, Deladoëy J. Clinical case seminar in pediatric thyroid disease. *Endocr Dev.* 26:214-44, 2014.
224. Pohlenz, **Van Vliet G**, Deladoëy J. Developmental abnormalities of the thyroid. In: *Genetic Diagnosis of Endocrine Disorders*, 2nd edition (Roy E. Weiss and Samuel Refetoff, editors), in press, 2014.
- 225.* Magne F, Serpa R, **Van Vliet G**, Samuels ME, Deladoëy J. Somatic mutations are not observed by exome sequencing of lymphocyte DNA from monozygotic twins discordant for congenital hypothyroidism with thyroid dysgenesis. *Horm Res in Pediatrics* 83:79-85, 2015.
- 226.* Brue T, Quentien M, Khetchoumian K, Bensa M, Capo-Chichi J, Delemer B, Balsalobre A, Nassif C, Papadimitriou DT, Pagnier A, Hasselmann C, Patry L,

- Schwartzentruber J, Souchon P, Takayasu S, Enjalbert A, **Van Vliet G**, Majewski J, Drouin J, Samuels ME. Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. *BMC Med Genet* 15:139, 2014.
227. **Van Vliet G**, Deladoëy J. Sublingual thyroid ectopy: similarities and differences with Kallmann syndrome. *F1000 Prime Rep.* 2015 Feb 3;7:20. doi: 10.12703/P7-20.
228. **Van Vliet G** and Deladoëy J. Interpreting minor variations in thyroid function or echostructure: treating patients, not numbers or images. *Pediatric Clinics of North America, Problems in Pediatric Endocrinology* (D. Daneman and M.R. Palmert, guest editors), in press 2015.

ABSTRACTS (only since 1989, listed once even if several presentations)

Abbreviations: ESPE: European Society for Pediatric Endocrinology, (LW)PES: (Lawson Wilkins) Pediatric Endocrine Society, CSEM: Canadian Society of Endocrinology and Metabolism, CPEG: Canadian Pediatric Endocrine Group

1. **Van Vliet G**, Robyn C, Bosson D. Study of the interaction between growth hormone releasing hormone and dopaminergic tone in normal adult men. The Endocrine Society, Seattle, June 1989.
2. **Van Vliet G**, Bergmann P. Study of the mechanisms whereby glucagon stimulates the secretion of growth hormone in man. The Endocrine Society, Atlanta, June 1990.
3. **Van Vliet G**, De Schepper J, Ghanem G, Rozenberg S, Bosson D. Clinical and biochemical heterogeneity of the syndrome of congenital ACTH unresponsiveness within a sibship. 3^d joint meeting, European Society for Pediatric Endocrinology (ESPE)/Lawson Wilkins Pediatric Endocrine Society (LWPES), Jerusalem, October 1989.
4. Chanoine JP, **Van Vliet G** and the Belgian Study Group for Pediatric Endocrinology. Rapidly waning effect of growth hormone (GH) treatment in short normal children and relative resistance to GH autofeedback. ESPE, Vienna, September 1990.
5. Heinrichs C, Bergmann P, Elmer C, Christophe C, **Van Vliet G**. Seizures during infancy as only clinical sign of familial isolated hypoparathyroidism with severe radiological manifestations. ESPE, Vienna, September 1990.
6. **Van Vliet G**, Bernier D, Yamamoto LN. Growth and ontogeny of plasma insulin-like growth factor-I in genetically obese rats. The Endocrine Society, Washington, D.C., 1991.
7. Nguyen-Yamamoto LN, Deal CL, Finkelstein JA, **Van Vliet G**. Increased response of IGF-I to GH in obese Zucker rats: a post-receptor phenomenon. The Endocrine Society, San Antonio, 1992.
8. Dubuis J-M, Deal CL, Ledru E, **Van Vliet G**. Normal plasma insulin-like growth factor-I concentration despite low growth hormone secretion in the genetically obese Zucker rat is not related to increased liver GH receptor expression. The Endocrine Society, Las Vegas, June 1993.
9. Pacaud D, Huot C, Gattereau A, Brown RS, Glorieux J, Dussault JH, **Van Vliet G**. Outcome of three siblings with antibody-mediated transient congenital hypothyroidism. 4th joint meeting, LWPES/ESPE, San Francisco, June 1993.
10. Dubuis J-M, Deal CL, Goodyer CY, Drews R, Asa S, **Van Vliet G**, Collu R. Mammosomatotroph adenoma and gigantism in an 8-year-old boy: pathophysiological aspects. 4th joint meeting, LWPES/ESPE, San Francisco, June 1993.
11. Lacroix A, Verdy M, **Van Vliet G**, Carlson NL, Myers S, Anderson L, Simpson NE. Coségrégation de la maladie de Hirschprung avec des marqueurs

- génétiques du chromosome 10 dans une famille atteinte du MEN 2A. Club de recherches cliniques du Québec, Pointe-au-Pic, Québec, September 1993.
12. Haney I, Deal CL, Hume H, **Van Vliet G**. Langerhans cell histiocytosis presenting with isolated endocrine gland involvement. Collège royal des médecins et chirurgiens du Canada, Vancouver, September 1993.
 13. Huot C, Dubois J, Saint-Vil D, Russo P, **Van Vliet G**. Focal pancreatic adenomatosis causing hyperinsulinism of neonatal onset: diagnosis by pancreatic venous sampling. Collège royal des médecins et chirurgiens du Canada, Vancouver, September 1993.
 14. Dubuis J-M, Richer F, Glorieux J, Deal CL, Dussault JH, **Van Vliet G**. Should all patients with congenital hypothyroidism (CH) be treated with 10-15 µg/kg.day of levothyroxine? Society for Pediatric Research, Seattle, May 1994.
 15. Catellier P, Pacaud D, **Van Vliet G**. Acute stress markedly increases plasma 17-OH progesterone (17-OHP) in infants born at term and aged 0.5 to 7.6 months: a pitfall in the diagnosis of congenital adrenal hyperplasia (CAH). Society for Pediatric Research, Seattle, May 1994.
 16. Chanoine J-P, Rebuffat E, Kahn A, **Van Vliet G**. Decreased growth hormone (GH) response to glucagon in infants after an apparent life threatening event (ALTE). Society for Pediatric Research, Seattle, May 1994.
 17. Pacaud D, Tannenbaum GS, **Van Vliet G**, Epelbaum J, Bluet-Pajot MT, Deal CL. Differential effects of GH excess on growth hormone receptor (GHR) and growth hormone binding protein (GHBP) expression in GH-hypersecreting rats. The Endocrine Society, June 1994.
 18. Videau C, Epelbaum J, Dubuis J-M, **Van Vliet G**, Tannenbaum GS. Sex-related alterations in hypothalamic GHRH mRNA- but not SRIH mRNA-containing cells in genetically obese Zucker rats. 3^d International Congress of Neuroendocrinology, Budapest, Hungary, July 1994.
 19. Pacaud D, **Van Vliet G**, Delvin EE, Dupuis C, Garel L, Chad Z, Delange F, Deal CL. A third world disease in North America: severe diet-induced iodine deficient goitrous hypothyroidism in a 6 yr old atopic boy. Collège Royal des Médecins et Chirurgiens du Canada, September 1994.
 20. Tannenbaum GS, Tzanela M, **Van Vliet G**, Guyda H. Un prétraitement par somatostatine (SRIF) augmente la réponse de l'hormone de croissance (GH) à la somatocrinine (GRF): efficacité potentielle dans le diagnostic de la déficience en GH. XXXVI^e réunion annuelle du club de recherches cliniques du Québec, September 1994.
 21. Taback S, Collu R, Deal CL, Salisbury S, Guyda H, **Van Vliet G**. Variability of final adult height (FAH) in Turner syndrome (TS): Estrogen (E2) replacement alone and in combination with growth hormone (GH). Society for Pediatric Research, San Diego, May 1995.
 22. Dubuis J-M, Deal CL, Tsagaroulis P, Clark RG, **Van Vliet G**. Effects of GH and/or IGF-I infusions on growth, organ weights and body fat in obese Zucker rats. The Endocrine Society, Washington, D.C., June 1995.
 23. Alos N, Lambert R, Huot C, **Van Vliet G**. Scintigraphy is not helpful in the diagnosis of pediatric Hashimoto's thyroiditis (HT). ESPE, Edinburgh, June 1995.
 24. Delvin EE, Huot C, **Van Vliet G**, Bonin A, St-Vil D, Dubois J. Extemporeal insulin measurement during pancreatic venous catheterization. American Association of Clinical Chemistry, 1995.
 25. Delvin EE, Huot C, Racine J-F, **Van Vliet G**. Assessment of stimulated 22kDa growth hormone (GH) secretion in children with idiopathic short stature (ISS) and in children with pituitary disorders. European Congress of Clinical Chemistry, 1995.

26. Gagné N, **Van Vliet G**, Blaquièrre E, Huot C, Collu R, Deal C. GnRH analogues (GnRH-As) in combination with other hormone therapies in the management of short adolescents, Society for Pediatric Research, Washington, D.C., May 1996.
27. Taback SP, **Van Vliet G**, Guyda HJ. Research priorities and designs in the pharmacologic manipulation of human growth. 10th International Congress of Endocrinology, San Francisco, June 1996.
28. Barnes R, Polychronakos C, **Van Vliet G**, Deal C. GnRH analog treatment in idiopathic central precocious puberty (ICPP) presenting in girls after age five years. Collège Royal des Médecins et Chirurgiens du Canada, Halifax, September 1996.
29. Dubuis JM, Collu R, Huot C, Deal C, **Van Vliet G**. Macroprolactinoma in a boy with Prader-Willi syndrome. ESPE, Montpellier, September 1996.
30. Collu R, Tang J-Q, Castagné J, Lagacé G, Masson N, Deal CL, Huot C, **Van Vliet G**. Isolated central hypothyroidism caused by inactivating mutations in the thyrotropin-releasing hormone gene (*TRHR*). ESPE, Montpellier, September 1996.
31. Gagné N, Paquette J, Oligny L, **Van Vliet G**, Deal C. Pediatric adrenocortical tumors: structural DNA abnormalities and insulin-like growth factor-II overexpression as early tumor events. 5th Joint Meeting, ESPE/LWPES, Stockholm, June 1997.
32. Ward L, Huot C, Lambert R, Delvin E, Deal C, Collu R, **Van Vliet G**. Hyperthyroidism in children and adolescents: should radioiodine be the first line therapy? 5th Joint Meeting, ESPE/LWPES, Stockholm, June 1997.
33. Alos N, Simard J, Legault L, **Van Vliet G**. Severe 3-beta-hydroxysteroid dehydrogenase (3 β HSD) deficiency due to a novel Ala10Glu homozygous mutation in the 3 β HSD gene (*HSD3 β 2*) in a 46 XX patient. 5th Joint Meeting, ESPE/LWPES, Stockholm, June 1997.
34. Ward L, Chavez M, Huot C, Lecocq P, Martial JA, **Van Vliet G**. Severe combined pituitary hormone deficiency due to a PIT-1 mutation in a French-Canadian boy. 5th Joint Meeting, ESPE/LWPES, Stockholm, June 1997.
35. Gagné N, Parma J, Deal C, Vassart G, **Van Vliet G**. Apparent congenital athyreosis due to compound heterozygosity for inactivating mutations in the thyrotropin-receptor gene. 5th Joint Meeting, ESPE/LWPES, Stockholm, June 1997.
36. Desrochers M, Moisan AM, Alos N, Mebarki F, Turgeon C, Gingras S, **Van Vliet G**, Morel Y, Simard J. Unexpected repercussions of missense mutations in type II 3 β -hydroxysteroid dehydrogenase gene. The Endocrine Society, New Orleans, June 1998.
37. Tiosano D, Heinrichs C, **Van Vliet G**, Peri M, Hochberg Z. The clinical syndrome of apparent athyreosis in severe thyrotropin resistance (RTSH). ESPE, Warsaw, September 1999.
38. Tenoutasse S, Deal C, Ledru E, **Van Vliet G**. Increased IGF-IB mRNA in hepatocytes from obese Zucker rats: a clue to the growth hormone-independent growth of obesity? ESPE, Warsaw, September 1999.
39. Devos H, Rodd C, Gagne N, Laframboise R, **Van Vliet G**. Thyroid dysgenesis: sex ratios and associated malformations, ESPE, Warsaw, September 1999.
40. Mircescu H, Parma J, Huot C, Deal C, Oligny LL, Vassart G, **Van Vliet G**. Hyperfunctioning malignant thyroid nodule in an eleven-year-old girl: Pathological And Molecular Study. ESPE, Brussels, September 2000.
41. Vincent MA, Rodd C, Dussault JH, **Van Vliet G**. Very low birth weight newborns do not need repeat screening for congenital hypothyroidism. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.

42. Simoneau-Roy J, Marti S, Deal C, Huot C, Robaey P, **Van Vliet G**. Normal developmental outcome at school entry in severe congenital hypothyroidism treated with early high-dose levothyroxine. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
43. Perry RJ, Heinrichs C, Bourdoux P, Dussault JH, Vassart G, **Van Vliet G**. Discordance of monozygotic twins for congenital hypothyroidism: implications for screening and for molecular pathophysiology. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
44. McEachern RR, Houle A-M, **Van Vliet G**. Lost and Found Testes-Finding Functional Testicular Tissue in Children after Presumed Bilateral Anorchia and/or Gonadectomy. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
45. Simoneau-Roy J, Laberge J-M, Bernard C, **Van Vliet G**. Mixed gonadal dysgenesis with gonadoblastoma at 3 months of age and lack of increase in FSH after bilateral gonadectomy. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
46. Perry RJ, Huot C, **Van Vliet G**, Deal C. Primary adrenal insufficiency in children: twenty years of experience. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
47. Huot C, Truong TL, St-Louis P, **Van Vliet G**, Delvin EE. Fasting insulin and leptin levels as predictors of glucose tolerance in obese children and adolescents. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
48. McEachern R, Fortier I, Deal C, **Van Vliet G**, Huot C. Pitfalls in using self-reported versus measured heights in the evaluation of growth in children. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
49. The IMAGINE-TS Study Group (including **Van Vliet G**, member of the steering committee). Meta-analysis of growth hormone treatment in patients with Turner syndrome, aged 5-10 years. 6th Joint Meeting LWPES/ESPE, Montréal, July 2001.
50. McEachern R, Pulichino A-M, Deal C, **Van Vliet G**, Drouin J. A novel mutation of the pituitary transcription factor, T-PIT: more than just ACTH deficiency? Society for Pediatric Research, Baltimore, May 2002.
51. Pulichino AM, Lamolet B, Brue T, Riepe FG, Partsch CJ, Sippel WG, **Van Vliet G**, Drouin J. A new pituitary transcription factor, TPit, determines the POMC-expressing lineages. The Endocrine Society, San Francisco, June 2002.
52. Marti S, Robaey P, Simoneau-Roy J, Leroux S, Alvarez M, **Van Vliet G**. An ERPS study of differential brain maturation in children treated for congenital hypothyroidism. International Congress of Psychophysiology, Montreal, July 2002.
53. Netchine I, Heinrichs C, Thibaud N, Christophe C, **Van Vliet G**, Sobrier M-L, Amselem S. Aplasia of the anterior pituitary and optic nerve coloboma due to a germline retrotransposition insertion event disrupting the homeodomain of HESX1. ESPE, Madrid, September 2002.
54. **Van Vliet G**, Léger J, Norton J, Larroque B. Estimation of severity of congenital hypothyroidism at diagnosis by bone maturation: should a sex-specific criterion be used? ESPE, Madrid, September 2002.
55. **Van Vliet G**, Deal C, Crock P, Robitaille Y, Oligny LL. Sudden death in GH-treated children with Prader-Willi syndrome. ESPE, Ljubljana, September 2003.
56. Fillion M, Djemli A, Lambert R, Delvin E, **Van Vliet G**. How frequent is true congenital athyreosis? ESPE, Ljubljana, September 2003.
57. Fillion M, Chabot G, Powell J, **Van Vliet G**, Alos N. Pamidronate: first choice treatment for hypercalcemia in subcutaneous fat necrosis. ESPE, Ljubljana, September 2003.

58. Vallette-Kasic S, Pulichino AM, Gueydan M, Barlier A, David M, Nicilono M, Malpuech G, Déchelotte P, Deal C, **Van Vliet G**, De Vroede M, Riepe FG, Partsch CJ, Sippel WG, Berberoglu M, Atasay B, de Zegher F, Beckers D, Kyllö J, Donohoue P, Fassnacht M, Hahner S, Noordam K, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Léger J, Brauner R, Heinrich JJ, Cummings E, Riddell C, Enjalbert A, Brue T, Drouin J. Congenital isolated ACTH deficiency, an underestimated cause of neonatal death, explained by TPIT mutations. The Endocrine Society, New Orleans, June 2004.
59. Spiegelblatt L, Legault L, Fournier A, Parma J, Vassart G, **Van Vliet G**. Recovery from mitral insufficiency after removal of an autonomous hyperfunctioning thyroid nodule causing hyperthyroidism in a 4-year-old girl. ESPE, Basel, September 2004.
60. Eugène D, **Van Vliet G**. Sexual dimorphism of thyroid function in infants with congenital hypothyroidism due to thyroid ectopy. ESPE, Basel, September 2004.
61. Couture Y, Arthus MF, Fujiwara TM, Lonergan M, Deal C, **Van Vliet G**, Bichet DG. Severe Early-Onset Autosomal Recessive Neurohypophyseal Diabetes Insipidus: Report Of Novel Arginine Vasopressin-Neurophysin II Mutations And Comparison With Dominant Forms. Canadian Pediatric Society, June 2005.
62. Perry RJ, Alos N, Huot C, Deal C, **Van Vliet G**. Audit of quality of referral of children with short stature to the pediatric endocrinology outpatient clinic of a tertiary care center. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
63. Gagné J, Deal C, **Van Vliet G**, Huot C, Alos N, Lacroix A, Martin M, Delvin E, Oligny L, Lambert R, St-Vil D. Is completion of prophylactic thyroidectomy by radioiodine useful in patients at risk of multiple endocrine neoplasia 2 (MEN2)/Familial Medullary Thyroid Cancer (FMTC)? 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
64. Scott R, Huang N, Miller WL, **Van Vliet G**. Phenotypic spectrum of POR mutations in two French-Canadian families. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
65. Rovet J on behalf of the Canadian GH Advisory Committee (including **Van Vliet G**, member of the steering committee of the study). Impact of growth hormone supplementation on psychosocial and behavioral functioning at adult height in Turner syndrome: results of the Canadian randomized controlled trial. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
66. Amed S, Delvin E, Hamilton J, on behalf of the Canadian Pediatric Endocrine Group (including **Van Vliet G**). CPEG comparison of Growth Hormone immunoassays. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
67. Lawson M, Chanoine JP, on behalf of the Canadian Pediatric Endocrine Group (CPEG) (including **Van Vliet G**). A Survey of the Canadian Pediatric Endocrine Group (CPEG) on the prescription of Growth Hormone to children with idiopathic short stature (ISS). 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
68. Taback SP, Guyda HJ, **Van Vliet G**. Health-related quality of life of young adults with Turner syndrome following a randomized controlled trial of growth hormone to adult height. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
69. Duong L, Ouqfi A, Naud L, Migliore M, **Van Vliet G**, Huot C, Alos N, Cheriet F, and Deal C. Keeping Track of Endocrinology Out-Patients: a User-Friendly, Web-Based Application. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
70. Eugène D, Levac M-F, Décarie J-C, **Van Vliet G**, Deal C. An image is worth a thousand words: magnetic resonance imaging in growth hormone deficiency. 7th Joint Meeting ESPE/LWPES, Lyon, Sept 2005.
71. Costa T, Desilets V, Perreault G, **Van Vliet G**, Verellen-Dumoulin C, Sica REP.

- Skeletal dysplasia with muscle spasms: a new disorder? International Skeletal Dysplasia Society, 2005.
72. Deladoëy J, Deal C, **Van Vliet G**. Molecular mechanism of thyroid dysgenesis. Canadian Pediatric Endocrine Group, Edmonton, February 2006.
 73. Fillion M, Deal C, **Van Vliet G**. Normal testosterone surge in male infants with Prader-Willi syndrome. ESPE, Rotterdam, June 2006.
 74. M Fillion, Cheri Deal, **Van Vliet G**. Potential benefits and risks of growth hormone treatment in children with Prader-Willi syndrome. ESPE, Rotterdam, June 2006.
 75. Fillion M, Deal C, **Van Vliet G**. Normal testosterone surge in male infants with Prader-Willi syndrome. ESPE, Rotterdam, June 2006.
 76. Deladoëy J, Vuissoz J-M, Deal C, **Van Vliet G**. Comment fonctionne une désiodinase? Une étude bioinformatique. Congrès Annuel des Étudiants Gradués, Centre de Recherche de l'Hôpital Sainte-Justine, June 2006.
 77. Olivier P, Francoeur D, Rypens F, Oligny LL, **Van Vliet G**. Virilizing ovarian tumor in a 12-years-old girl: the importance of ultrasonography. Canadian Society of Endocrinology and Metabolism, Toronto, Ontario, October 2006.
 78. Scott RR, Huang N, **Van Vliet G**, Miller WL. Heterozygosity for mutations in P450 oxidoreductase deficiency complicates the presentation of classical, salt-wasting congenital adrenal hyperplasia. Canadian Society of Endocrinology and Metabolism, Toronto, Ontario, October 2006.
 79. Moussa A, **Van Vliet G**, Farrell C, Carrière B, au nom du Comité d'Admission. Admissions en résidence de pédiatrie à l'Université de Montréal: portrait de la dernière décennie. Forum International Francophone de Pédagogie Médicale, Mont Tremblant, Québec, Mars 2007.
 80. Girardin C, Huot C, Rypens F, Houle AM, Brochu P, Wilson M, New M, **Van Vliet G**. Ambiguous genitalia: an ambiguous case.... Canadian Pediatric Endocrine Group (CPEG), London, Ontario, April 2007.
 81. Rottembourg D, Carceller AM, Vadeboncoeur D, Garneau PY, **Van Vliet G**, Huot C and Alos N. The first case of bariatric surgery in a 14-year-old boy with hypothalamic obesity at the Sainte-Justine Hospital: major weight loss but significant short term complications. CPEG, London, Ontario 2007.
 82. Deladoëy J, Vuissoz JM, **Van Vliet G**. Analyse in silico des interactions entre l'hormone de croissance et son récepteur. Congrès Annuel des Étudiants Gradués, Centre de Recherche de l'Hôpital Sainte-Justine, May 2007.
 83. Deladoey J, Oligny LL, Payot A, Laberge S, Parma J, Vassart G, **Van Vliet G**. Lethal respiratory failure and mild primary hypothyroidism in a term neonate due to a heterozygous mutation in TTF1: clinical description and autopsy results. Pediatric Academic Societies, Toronto, May 2007.
 84. Tadjine M, **Van Vliet G**, Fournet JC, Bourdeau I. Pediatric aldosterone-secreting adrenocortical tumor associated with a beta-catenin gene mutation. Endocrine Society, Toronto, June 2007.
 85. Pitteloud N, Cole L, Sidis I, Plummer L, Hughes V, Huot C, Alos N, Lavoie H, Speiser P, Takeshita A, **Van Vliet G**, Dwyer A, Zhou Q-Y, Crowley W. Mutations in the gene for prokinectin 2 (PROKR2) cause both Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (nIHH) Endocrine Society, Toronto, June 2007.
 86. Khatchadourian K, Alos N, Huot C, **Van Vliet G**, Deal C. Impact of Patient Characteristics and Clinical Factors on Decision to Initiate Growth Hormone Treatment in Turner Syndrome. ESPE, Helsinki, June 2007.
 87. Deladoëy J, Pfarr N, Vuissoz JM, Parma J, Vassart G, Polhenz J, **Van Vliet G**. Pseudodominant inheritance of congenital thyroid dysmorphogenesis from TPO mutations in a non-consanguineous family: clinical, genetic and in silico

- studies. ESPE, Helsinki, June 2007.
88. **Van Vliet G**, Liu S, Kramer MS, for the Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. Decreasing Sex Difference in Birth Weight: A Potential Clue to Environmental Endocrine Disruption. Endocrine Society, June 2008.
 89. Girardin CM, Lemyre E, Alos N, Deal C, Huot C, **Van Vliet G**. 47, XXY at amniocentesis: what should the couple be told? ESPE, September 2008.
 90. Girardin CM, Deal C, Lemyre E, Beitel LK, Trifiro M, **Van Vliet G**. Molecular investigation of complete androgen insensitivity associated with a 47,XXY karyotype. ESPE, September 2008.
 91. Liu S, **Van Vliet G**, Pelletier L, Kramer MS, for the Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. Are boys becoming an endangered species? Society for Perinatal Epidemiology, September 2008.
 92. Saavedra J, Huot C, Boivin Y, **Van Vliet G**, Deal C, Alos N, Saint-Vil D. Outcome of children with thyroid lesions and benign findings at fine needle aspiration biopsy. Canadian Society of Endocrinology and Metabolism, Montreal, October 2008.
 93. Stoppa-Vaucher S, Alos N, Lapeyraque AL, Phan V, Rumsby G, **Van Vliet G**. Chronic hyponatremia in a 3-year-old boy with isolated hyperreninemic hypoaldosteronism. Canadian Society of Endocrinology and Metabolism, Montreal, October 2008.
 94. Stoppa-Vaucher S, Francoeur D, Grignon A, **Van Vliet G**, Deladoëy J. A 19-weeks fetus with non-immune hypothyroidism and goiter: treatment or observation? CPEG, Ottawa, February 2009.
 95. Abu-Khudir R, Paquette J, Libert F, Chanoine JP, Vassart G, **Van Vliet G**, Deladoëy J. Combined Analysis of Transcriptome, Methylome and Structural Genome Variants in Ectopic versus Eutopic Thyroid Tissues. Endocrine Society, June 2009.
 96. Leblieq C, Rottembourg D, Deladoëy J, **Van Vliet G**, Deal C. Are guidelines for glucocorticoid coverage being followed in patients with adrenal insufficiency during periods of stress? LWPES/ESPE, September 2009.
 97. Olivier P, Simoneau-Roy J, Francoeur D, Parma J, Vassart G, **Van Vliet G**. Contrasting hormonal phenotypes of Leydig cell tumors in a 9-year-old boy and in a 12-year-old girl. LWPES/ESPE, September 2009.
 98. Stoppa-Vaucher S, Djemli A, **Van Vliet G**. Undetectable AMH levels allow earlier diagnosis of anorchia than FSH. CPEG, Calgary, March 2010.
 99. Stoppa-Vaucher S., **Van Vliet G**, Deladoëy J. Variation by Ethnicity in the Prevalence of Congenital Hypothyroidism due to Thyroid Dysgenesis. ESPE, September 2010.
 100. Deladoëy J, Ruel J, Giguère Y, **Van Vliet G**. Lowering thyrotropin cutoff for newborn screening: Additional cases of congenital hypothyroidism are identified, but what do they really have? CPEG, Toronto, February 2011.
 101. Miraoui H, Feng B, Sykiotis G, Beenken A, Plummer L, Quinton R, Hughes V, **Van Vliet G**, Chanoine JP, Crowley WF Jr, Dwyer A, Sidis Y, Mohammadi M, Pitteloud N. Mutations in the FGF8 genetic network underlie a large proportion of isolated human GnRH deficiency. The Endocrine Society, June 2011.
 102. Wildi-Runge S, Deladoëy J, Bélanger C, Deal C, **Van Vliet G**, Alos N, Huot C. Can recovery from hypothalamic-pituitary-adrenal (HPA) axis suppression following supraphysiological doses of glucocorticoids be predicted? The Endocrine Society, June 2011.
 103. Chiniara L, Perry RJ, **Van Vliet G**, Deal C. Audit of the quality of referral of short children to the pediatric endocrinologist. CPEG, Winnipeg, February

- 2012.
104. Michaud S, Deladoëy J, Deal C, **Van Vliet G**. No Evidence for Central Hypothyroidism at Birth in Prader-Willi Syndrome (PWS). ESPE, Leipzig, Sep 2012.
 105. Samuels ME, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, Chouinard L, Schwartzentruber J, Djemli A, Delvin E, Deal CL, **Van Vliet G**, Majewski J, Deladoëy J. Isolated glucocorticoid deficiency caused by immunoreactive but biologically inactive ACTH. ESPE, Leipzig, Sep 2012.
 106. Manousaki D, Lemyre E, **Van Vliet G**, Deal CL, Deladoëy J. Phenotypic variability in familial GLI2 deletion. CPEG, Québec City, January 2013.
 107. Hasselmann C, Samuels M, Majewski J, Deal C, Huot C, **Van Vliet G**, Deladoëy J. Diagnostic mysteries solved by exome sequencing. International Pediatric Endocrinology meeting, Milan, September 2013.
 108. Manousaki D, Magne F, Bui H, **Van Vliet G**, Samuels ME, Deladoëy J. Thyroid ectopy in mother and daughter. CPEG, Montreal, February 2014.
 109. Hasselmann C, Samuels ME, **Van Vliet G**. GOLIATH, a variant of DAVID syndrome? ESPE, Dublin September 2014.
 110. Meijer IA, Michaud J, Tran L, Rossignol E, **Van Vliet G**, Deladoëy J, Chouinard S, Bernard G. Novel mutations in *TITF1* cause benign hereditary chorea, hypothyroidism and neonatal respiratory distress syndrome. Child Neurology Society, 2014.
 111. Perlsteyn M, Deladoëy J, **Van Vliet G**. Is the dose of Levothyroxine required to reach a euthyroid state really higher in school-age children with congenital vs. acquired hypothyroidism? CPEG, Halifax, February 2015.
 112. Capo-chichi JM, Khodja Y, Hasselmann C, Deladoëy J, Schwartzentruber J, Nassif C, Majewski J, **Van Vliet G**, Samuels ME. GOLIATH, a Variant of DAVID Syndrome, Is Associated with an Intronic Variant in IKBKE. PES, April 2015.
 113. Bourdet K, Valette S, Deladoëy J, **Van Vliet G**. Contrasting central diabetes insipidus due to preproAVP mutations: earlier onset of symptoms in recessive than in dominant forms. ESPE, October 2015.

INVITED LECTURES AND CONTINUING MEDICAL EDUCATION (since 1983)

- International Symposium on Advances in Human Growth Hormone Research, Baltimore, 1983: "Turner's syndrome and growth hormone: biochemical studies".
- 28èmes Journées Internationales H.P. Klotz d'Endocrinologie Clinique, Paris, 1985: "Utilisation diagnostique de la somatocrine: résultats d'une étude multicentrique européenne".
- Postgraduate Course, University of Milan, 1986: "Growth hormone in the treatment of short stature".
- Séminaires de la Division de Biologie de la Croissance et de la Reproduction, Université de Genève, 1986: "Études cliniques et expérimentales de la somatocrine dans les troubles de la croissance".
- European Society for Pediatric Endocrinology, Toulouse, 1987: "Growth hormone treatment in constitutional short stature".
- International Symposium on Growth and Growth disorders, Paris, 1987: "Hormonal changes during development in Turner syndrome".
- Food and Drug Administration, Bethesda, 1987. Presentation to the Advisory Panel on non-conventional uses of growth hormone.
- Séminaire d'Endocrinologie Pédiatrique, Hôpital des Enfants Malades, Paris, 1988: "Petites tailles essentielles: quelle est la place du traitement par hormone de croissance"?

- International Symposium on Diagnosis and Treatment of Growth Disorders, Naples, 1988: "Growth hormone treatment of children with non-growth hormone deficient short stature".
- NATO Advanced Research Workshop on Congenital Hypothyroidism, Brussels, 1988: "Treatment strategy and long-term follow-up of congenital hypothyroidism".
- Symposium "Groter met groeihormon?", Nieuwegijn, The Netherlands, 1988: "Somatomedines en andere groeifactoren".
- Conférencier Eli Lilly Canada, Université de Montréal, 1988: "Nouvelles formes de thérapie dans les retards de croissance".
- Workshop on Growth, Copenhagen, 1988: "Growth hormone and adipose tissue".
- International Symposium on Pediatric Endocrinology, Tokyo, 1988: "Studies with growth hormone releasing factor in children. Diagnostic and therapeutic implications".
- 8th International Congress of Endocrinology, Kyoto, 1988: "Growth hormone treatment of children with non-growth hormone deficient short stature".
- International Symposium on Evaluation of Diagnostic Protocols for Short Stature Patients, Vienna, 1988: "Usefulness and limitations of growth hormone releasing hormone as a diagnostic tool".
- International Symposium on Hormonal Control of Growth, Vienna, 1988: "Final height in GH-treated children. Role of initial factors".
- 5^{èmes} Journées Nationales de Pharmacologie Clinique, Giens, France, 1988: "Jalons du développement de l'hormone de croissance biosynthétique".
- Programma Vlaamse Universiteiten, Gent, Belgium: "Pubertas Praecox", 1/89.
- Corso Nazionale di Aggiornamento della Società Italiana di Endocrinologia e Diabetologia Pediatrica, Pisa, 1989: "Growth hormone treatment of children with non-growth hormone deficient short stature".
- 19th International Congress of Pediatrics, Paris, 1989: "Perspectives pour l'usage de la somatocroinine chez l'enfant".
- International Symposium on Developmental Endocrinology, Geneva, 1989: "Use of growth hormone in the management of growth disorders".
- Roundtable Discussion Group on Current Issues in Pediatric Endocrinology, Dallas, 1990: "Metabolic indicators of growth hormone responsiveness".
- International Symposium on Diagnosis and Treatment of Short Stature, Firenze, 1990: "Side effects of growth hormone therapy".
- 29^{ème} Congrès des Pédiatres de Langue Française, Lyon, 1990: "Traitement à l'hormone de croissance des filles présentant un syndrome de Turner".
- Club Croissance, Courchevel (France), 1991: "Croissance pubertaire normale et pathologique".
- 34^{èmes} Journées Internationales H.P. Klotz d'Endocrinologie Clinique, Paris, 1991: "Aspects cliniques du développement pubertaire normal".
- Joint Meeting New England Collaborative Group on Congenital Hypothyroidism-Québec Network for Genetic Medicine (Portland, ME, 1991): "Follow-up of congenital hypothyroidism: update on the Quebec experience".
- Association des Biochimistes Cliniques du Québec, Magog, 1992: "La fonction thyroïdienne et ses anomalies de la naissance à l'adolescence".
- International Roundtable, London, April 1992: "Growth hormone therapy in Turner syndrome" (invited as discussant).
- Joint Meeting New England Collaborative Group on Congenital Hypothyroidism-Québec Network for Genetic Medicine, Quebec (Quebec), October, 1992 (invited as discussant).
- 14th International Symposium on Growth and Growth Disorders, Budapest

- (Hungary), October 23-24, 1992 (invited to give the symposium summary).
- Association des Pharmaciens des Établissements de Santé du Québec, Novembre 1992: "Désordres de la croissance".
- Association du Syndrome de Turner du Québec, Janvier 1993: "L'hormone de croissance et le syndrome de Turner, où en sommes-nous cinq ans après?".
- Family Workshop on Growth Disorders, Montreal, Avril 1993. "Carence en hormone de croissance: diagnostic et traitement".
- Formation pédiatrique continue de Montréal, Laval, Mai 1993: "Les courbes de croissance: quand s'inquiéter, quand référer?"
- Growth and Growth Disorders: a Nursing Perspective, Quebec, May 1993: "Update on growth hormone therapy and leukemia and tumor recurrence".
- Joint Meeting, New England Collaborative Group on Congenital Hypothyroidism-Quebec Network for Genetic Medicine, Cape Cod, October 1993: "Outcome of fetal hypothyroidism: will the IQ gap ever be closed?".
- Clinical Issues in Growth Disorders. Evaluation, diagnosis, therapy. Lisbon, Portugal, January 1994 (organized by Prof. R. Rappaport, Paris): "GH secretion and body weight: clinical consequences".
- Vrije Universiteit Brussel, March 1994. "Gebruik van groeihormoon bij meisjes met Turner syndroom" (Pediatric Grand Rounds).
- US Humatropes investigators' meeting, Scottsdale, AZ, April 1994. "Growth hormone treatment, adult height and psychosocial adjustment in Turner syndrome: why we need controlled studies".
- Third International Turner's Syndrome Contact Group Meeting, Toronto, May 1994. "Growth hormone treatment and adult height in subjects with Turner's syndrome: do we need controlled studies?".
- Fourth International Symposium on Turner's Syndrome, Sweden, May 1995: "Growth hormone treatment, adult height and psychosocial adjustment in Turner syndrome: why we need controlled studies".
- Université de Genève, February 1996: "Indications actuelles et futures du traitement à l'hormone de croissance chez l'enfant" (Pediatric Grand Rounds).
- University of California, San Francisco, December 1996:
 - "Congenital hypothyroidism: new data on pathophysiology and outcome" (Endocrine Grand Rounds).
 - "Congenital hypothyroidism: a continuing challenge for the pediatrician" (Pediatric Grand Rounds).
- International Symposium "A current review of pediatric endocrinology", Washington, D.C, May 1997:
 - "Growth Hormone secretagogues".
 - "New concepts of obesity".
- Kabi International Growth Study (KIGS) - Investigators Meeting, Miami, December 97: "Ten years of KIGS within the progress of growth research" (round table).
- Séminaires d'Endocrinologie Pédiatrique, Hôpital des Enfants-Malades, Paris, janvier 1998: "Bases moléculaires de l'hypothyroïdie congénitale".
- Institut de Recherche Interdisciplinaire, Université Libre de Bruxelles, janvier 1998: "Hypothyroïdies centrales et périphériques: nouveaux mécanismes moléculaires".
- Pediatric endocrinology up-to-date: Diagnosis and treatment of GH deficiency in children and adolescents, 10 years after the availability of recombinant hGH: towards a consensus, Pisa, Italy, March 1998. "Predictors of treatment efficacy".
- European Thyroid Symposium, Pisa, Italy, April 1998. "Neonatal Hypothyroidism: treatment and outcome".
- Formation Pédiatrique Continue de Montréal, Novembre 1998: "Anomalies de la

croissance physique chez l'adolescent: quels indices faut-il rechercher lors de l'analyse de la courbe de croissance?"

- Annual Canadian Pediatric Endocrine Group Meeting, Québec City, February 1999. "Recent data on the growth and development of children with congenital hypothyroidism".
- Association française pour le dépistage et la prévention des handicaps de l'enfant, Tours, mai 1999: "Régulation de la fonction thyroïdienne chez le prématuré et dépistage de l'hypothyroïdie congénitale".
- Association des médecins endocrinologues du Québec, Magog, mai 1999: "Retard Pubertaire".
- Grand Rounds, Hospital for Sick Children, Toronto, June 1999: "Congenital hypothyroidism: recent data on molecular pathophysiology and developmental outcome".
- Division of Endocrinology, Hospital for Sick Children, Toronto, June 1999: "Obesity and growth hormone-independent growth: lessons from an animal model".
- Atlantic Health Systems (New Jersey, USA), October 1999:
 - "Congenital hypothyroidism: a continuing challenge for pediatricians" (Pediatric grand rounds).
 - "Molecular defects resulting in congenital hypothyroidism: lessons from patients and from knock-out mice" (Endocrinology grand rounds).
- Jewish General Hospital, Mc Gill University, Montreal, November 1999: "Molecular basis of thyroid dysgenesis" (Endocrinology rounds).
- Children's Hospital and Regional Medical Center, Seattle, WA, January 2000: "New molecular mechanisms of central and peripheral hypothyroidism: implications for screening and evaluation of newborns" (Endocrinology rounds).
- University of British Columbia Children's Hospital, Vancouver, January 2000: "Molecular pathophysiology of congenital hypothyroidism: lessons from patients and from knock-out mice" (Endocrinology/Genetics rounds).
- Association Belge des Hôpitaux, Bruxelles, février 2000: "Systèmes de santé belge et canadien: le témoignage d'un pédiatre universitaire belge à Montréal".
- Journées de Pédiatrie de l'Hôpital Sainte-Justine, mars 2000: "Comment évaluer les problèmes de croissance chez l'adolescent?".
- Hommage au Professeur Paul Malvaux, Université Catholique de Louvain, septembre 2000: "Défauts moléculaires conduisant à une hypothyroïdie congénitale: de la souris au patient".
- Third national workshop on screening for congenital hypothyroidism, Havana City, Cuba, October 2000: "Eradication of sporadic cretinism through systematic biochemical screening of newborns for congenital hypothyroidism: the Québec experience".
- Symposium: "Advances in Pediatric Endocrinology", Buenos Aires, March 2001:
 - "Congenital hypothyroidism: pathophysiology and developmental outcome".
 - "Pediatric hyperthyroidism: a therapeutic challenge".
- Endocrine Society, Denver, June 2001 (invited speaker): "Etiologies of congenital hypothyroidism: insights from clinical and molecular studies".
- Hommage au Professeur Renée Wolter, Bruxelles, Octobre 2001: "Hypothyroïdie congénitale: de la pathophysiologie moléculaire au devenir des patients".
- Séminaire d'Endocrinologie Pédiatrique, Institut Pasteur, Paris, Janvier 2002: "Thyroïde et prématurité".
- International Symposium on Controversial Issues in Pediatric Endocrinology, London, February 2002: "Advances in the diagnosis and treatment of congenital hypothyroidism".
- Canadian Pediatric Endocrine Group, Niagara-on-the-Lake, February 2002:

- "Molecular mechanisms of thyroid dysgenesis: a clinician's view".
- Groupe de Recherche sur la Thyroïde, Paris, Mars 2002: "Hypothyroïdies congénitales: de la pathophysiologie moléculaire au devenir des patients".
 - Département de Pédiatrie, Université de Genève, Mai 2002: "Hypothyroïdies congénitales: de la pathophysiologie moléculaire au devenir des patients".
 - Société Luxembourgeoise de Pédiatrie, Juin 2002: "Dépistage biochimique néonatal des maladies métaboliques: optimiser ceux qui existent ou en introduire de nouveaux?".
 - University of Manitoba, Winnipeg, November 2002:
 - Pediatric Grand Rounds: "Congenital hypothyroidism: from molecular pathophysiology to developmental outcome".
 - Meeting with families: "Congenital hypothyroidism: its causes and consequences".
 - Université Libre de Bruxelles, Belgium, December 2002:
 - Endocrinology Grand Rounds: "Progrès récents dans la génétique moléculaire des hypothyroïdies congénitales".
 - Interdisciplinary Research Institute: "L'organogénèse de la thyroïde vue par un clinicien".
 - Canadian Pediatric Endocrine Group, February 2003: "The case against biochemical screening for congenital adrenal hyperplasia".
 - Sociedad Latino-Americana de Endocrinología Pediátrica, Cancún, Sept. 2003:
 - "Congenital hypothyroidism" (plenary).
 - "Treatment of pediatric Graves' disease" (summer school course).
 - Joint Meeting of the Cuban and Spanish Societies for Pediatric Endocrinology, Havana, Cuba, November 2003:
 - "Molecular aspects of congenital hypothyroidism".
 - "The case against biochemical screening for congenital adrenal hyperplasia".
 - Journées de Pédiatrie de Sainte-Justine, décembre 2003: "La courbe de croissance, 4^{ème} signe vital".
 - Canadian Society for Endocrinology and Metabolism, Quebec, October 2004. "Normal and abnormal development of the thyroid gland: molecular mechanisms".
 - Congreso Chileno de Endocrinología y Diabetes, Concepción, Chili, November 2004:
 - "Molecular mechanisms of congenital hypothyroidism".
 - "Must the preterm infant be screened more than once for congenital hypothyroidism and treated for hypothyroxinemia?"
 - McGill University Health Center Charlotte Laplante-Branchaud annual lectureship in perinatal endocrinology, April 2005: "Congenital hypothyroidism: window into thyroid and brain development".
 - Journée-découverte en sciences de la santé de Pfizer Canada et du Temple de la renommée médicale canadienne, Montréal, May 2005. "Prévention de la déficience intellectuelle: l'exemple de l'hypothyroïdie congénitale".
 - 13th International Thyroid Congress, Buenos Aires, Argentina, October-November, 2005: "Molecular mechanisms of thyroid dysgenesis in humans".
 - McGill University Health Center Combined Endocrinology Rounds, December 2005: "Challenges in congenital hypothyroidism: understanding pathophysiology, optimizing outcome".
 - Quebec Thyroid Club, January 2006: "Hypothyroïdie congénitale: fenêtre sur le développement de la thyroïde et du cerveau".
 - Canadian Pediatric Endocrine Group Meeting, February 2006: "Use of growth hormone in children with Prader-Willi syndrome: a review of safety concerns and of clinical experience at the Ste-Justine Hospital".

- Brown University, Providence, RI, USA, Endocrinology Grand Rounds, April 2006: "Congenital hypothyroidism: window into thyroid and brain development".
- Belgian Thyroid Club, April 2006: "Challenges in congenital hypothyroidism: understanding pathophysiology, optimizing outcome".
- 6th International Society for Neonatal Screening, Japan, September 2006. "Optimal treatment of patients with congenital hypothyroidism detected by screening".
- Seattle Children's Hospital, Endocrinology Rounds, February 2007. "Congenital hypothyroidism: window into thyroid and brain development".
- International Workshop on Assessing Endocrine-Related Endpoints within the First year of Life. Ottawa, April-May 2007 (invited to present the need to re-evaluate perinatal iodine intake in the Canadian population).
- Pediatric Academic Societies, Toronto, May 2007. "Genetics and epigenetics of congenital hypothyroidism".
- Pediatric Grand Rounds, Université de Sherbrooke, Mai 2007. "Hypothyroïdie congénitale: physiopathologie moléculaire, dépistage et devenir des patients".
- Pediatric Grand Rounds, UBC, Vancouver, September 2007: "Challenges in congenital hypothyroidism: understanding pathophysiology, optimizing outcome".
- Pediatric Endocrinology Symposium, SUNY Downstate medical Center, Brooklyn, February 2008: "Current Approach to Congenital Hypothyroidism".
- Second ESPE Advanced Seminar in Developmental Endocrinology, Paris, April 2008: "Congenital hypothyroidism from thyroid dysgenesis: a non-Mendelian condition? Clinical background".
- IX Congreso Anual de la Sociedad Mexicana de Endocrinología Pediátrica, August 2008. "Turner syndrome, adult height and psychosocial adaptation: what is the role of growth hormone supplementation?".
- IX Congreso Anual de la Sociedad Mexicana de Endocrinología Pediátrica, August 2008. "Hipotirodismo Congénito: un constante desafío".
- 47th Annual Meeting of the European Society for Paediatric Endocrinology, Istanbul, Turkey, September 2008. "Screening for congenital hypothyroidism in industrialized countries".
- George Lowrey Lecture in Pediatric Endocrinology, University of Michigan, Ann Arbor, October, 2008: "Congenital hypothyroidism: window into thyroid and brain development".
- Pediatric Endocrinology Conference, University of Michigan, October 2008: "The case *against* biochemical screening of newborns for congenital adrenal hyperplasia".
- 13th International Congress of Endocrinology, Rio de Janeiro, Brazil, November 2008, Meet-the-Professor: "Management of congenital hypothyroidism".
- Royal College Professor, Pediatric Endocrinology Association for Research and Learning, Vancouver, March 2009:
 - "Turner syndrome, adult height and psychosocial adaptation: what is the role of growth hormone supplementation?".
 - "Congenital hypothyroidism: window into thyroid and brain development".
- 8th Joint meeting of the Lawson Wilkins Pediatric Endocrine Society and of the European Society for Pediatric Endocrinology, New York, September 2009. "Screening for thyroid disorders in premature neonates".
- Canadian Society for Endocrinology and Metabolism, Montreal, October, 2009: "The case *against* biochemical screening of newborns for congenital adrenal hyperplasia".
- Sociedad Argentina de Endocrinología y Metabolismo, Buenos Aires, November 2009:

- "Congenital hypothyroidism: From Paracelsus to molecular diagnosis"
- "Treating fetal endocrine disorders through the mother"
- "Screening of newborns for congenital adrenal hyperplasia: yes or no?"
- International Society of Neonatal Screening, Cancun, December 2009: "Do we need specific guidelines for congenital hypothyroidism screening in premature/low birth weight newborns?"
- Canadian Pediatric Endocrine Group, Calgary, March 2010. "The case against the use of growth hormone in children with Prader-Willi syndrome".
- Pediatric Academic Societies, Vancouver, May 2010: "Thyroid highlights of the year".
- 50th Anniversary of the "Fundación de Endocrinología Infantil", Buenos Aires, May 2010:
 - "New advances in congenital hypothyroidism".
 - "Growth hormone treatment for children with Turner and Prader-Willi syndrome: from randomized trials to clinical use".
- Thyroid Foundation of Canada, Ottawa, June 2010: "Pediatric aspects of thyroid disease".
- Endocrine Society, San Diego, June 2010: "Screening for Congenital Hypothyroidism: Controversies and Global Challenges".
- 14th International Thyroid Congress, Paris, September 2010: "Non-Mendelian mechanisms of thyroid dysgenesis".
- Conférences hebdomadaires du Département de Pédiatrie, Université Laval, Québec, octobre 2010 (Pediatric Grand Rounds): "Utilisation raisonnée de l'imagerie dans les pathologies thyroïdiennes de l'enfant".
- Romanian Society for Endocrinology, Postgraduate course on growth disorders, Bucharest, October 2011: "Thyroid disorders and growth".
- Conférence hebdomadaire du Département de Pédiatrie, Université de Montréal, octobre 2011 (Pediatric Grand Rounds): "Les courbes de croissance de l'Organisation Mondiale de la Santé vues par les pédiatres-endocrinologues".
- ESPE Consensus Meeting on Congenital Hypothyroidism, Rome, November 2011: invited to chair the group reviewing data on outcome.
- Centre Hospitalier de Saint-Jérôme, Mai 2012: "Courbes de croissance: lesquelles utiliser? quand s'inquiéter? quels tests demander?".
- CSEM, October 2012: "The case against universal screening for hypothyroidism during pregnancy".
- Sociedad Latino-Americana de Endocrinología Pediátrica, Montevideo 2012:
 - "Is the incidence of congenital hypothyroidism *really* increasing?"
 - "Towards evidence-based prenatal counselling for Klinefelter syndrome".
- Laboratoire de dépistage néonatal sanguin du Québec, Québec, mars 2013: "Dépister l'hypothyroïdie congénitale: des patients, pas des chiffres".
- Canadian Newborn and Child Screening Symposium, Ottawa, April 2013: "Treating patients, not numbers: has screening for congenital hypothyroidism become too sensitive?" (keynote speaker).
- Clinical molecular diagnostics laboratory, Ste-Justine, May 2013: "Analyse moléculaire du récepteur à l'hormone thyroïdienne en pédiatrie: intérêt clinique et impact économique".
- Pediatric Academic Societies Topic Symposium on Non-Communicable Diseases & Global Health - Challenges & Opportunities in Pediatric Endocrinology in a Low Income Setting, Washington, D.C., May 2013: "Screening for congenital hypothyroidism in developing countries: why, when, how?"
- The Endocrine Society, San Francisco, June 2013:
 - Meet the professor session: "Girl? Boy? When the answer to the parents' first question in the delivery room is not obvious..."

- Clinical management session: "Management of Congenital Hypothyroidism" (Juliane Léger and Guy Van Vliet).
- The American Thyroid Association, San Juan, P.R., October 2013: "Congenital hypothyroidism: management of mild cases" (Meet-the-Professor).
- Canadian Association of Medical Biochemists - Médecins biochimistes du Québec Joint annual meeting, Montreal, October 2013: "Congenital hypothyroidism: treating patients, not numbers".
- Aga Khan Hospital/East Africa Medical School, Nairobi, Kenya, November 2013: "Screening for congenital hypothyroidism in emerging countries: why, when, how?"
- Pediatric Endocrine Society Clinical Update Course, Vancouver, May 2014: "Disorders of sex development: new genes and therapies".
- European Society for Pædiatric Endocrinology annual meeting, Dublin, Ireland, Sep 2014, Meet-the-Professor session: "Management of thyroid nodules".
- Pediatric Endocrine Society Delegation to Haiti, March 1-7, 2015:
 - *Dépistage de l'hypothyroïdie congénitale en pays émergents: pourquoi, quand, comment?* Presentation to the Ministry of Health.
 - *Hypo-et hyperthyroïdies pédiatriques*, Grand Rounds, Mirebalais University Hospital.